U.S. patent application number 10/552842 was filed with the patent office on 2007-03-08 for n-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor.
Invention is credited to Wilfried Braje, Karla Drescher, Herve Geneste, Roland Grandel, Andreas Haupt, Wilfried Lubisch, Daryl R. Sauer, Sean C. Turner, Liliane Unger.
Application Number | 20070054918 10/552842 |
Document ID | / |
Family ID | 33131380 |
Filed Date | 2007-03-08 |
United States Patent
Application |
20070054918 |
Kind Code |
A1 |
Braje; Wilfried ; et
al. |
March 8, 2007 |
N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for
the dopamine d3 receptor
Abstract
The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide
compounds of the general formula (I) in which Q is a bivalent,
6-membered heteroaromatic radical which possesses 1 or 2 N atoms as
ring members and which optionally carries one or two substituents
R.sup.a which is/are selected, independently of each other, from
halogen, CN, NO.sub.2, CO.sub.2R.sup.4, COR.sup.5,
C.sub.1--C.sub.4-alkyl and C.sub.1--C.sub.4-haloalkyl; Ar is phenyl
or a 6-membered heteroaromatic radical which possesses 1 or 2 N
atoms as ring members and which optionally carries one or two
substituents R.sup.b, which is/are selected from halogen, NO.sub.2,
CN, CO.sub.2R.sup.4, COR.sup.5, C.sub.1--C.sub.6-alkyl,
C.sub.2--C.sub.6-alkenyl, C.sub.2--C.sub.6-alkynyl,
C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl and
C.sub.1--C.sub.4-haloalkyl, with it also being possible for two
radicals R.sup.b which are bonded to adjacent C atoms of Ar to be
together C.sub.3--C.sub.4-alkylene; R.sup.1 is hydrogen,
C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-haloalkyl,
C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-hydroxyalkyl,
C.sub.1--C.sub.4-alkoxy-C.sub.1--C.sub.4-alkyl,
C.sub.3--C.sub.4-alkenyl or C.sub.3--C.sub.4-alkynyl; with the
radicals n, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 having
the meanings given in the patent claims, to the N-oxides and to the
physiologically tolerated acid addition salts of these compounds
and to pharmaceutical compositions which comprise at least one
N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one
of claims 1 to 10 and/or at least one physiologically tolerated
acid addition salt of I and/or an N-oxide of I, where appropriate
together with physiologically acceptable carriers and/or auxiliary
substances for treating diseases which respond to influencing by
dopamine D.sub.3 receptor antagonists or agonists, in particular
for treating diseases of the central nervous system and
disturbances of kidney function. ##STR1##
Inventors: |
Braje; Wilfried; (Rinteln,
DE) ; Haupt; Andreas; (Schwetzingen, DE) ;
Lubisch; Wilfried; (Heidelberg, DE) ; Grandel;
Roland; (Dossenheim, DE) ; Drescher; Karla;
(Dossenheim, DE) ; Geneste; Herve; (Neuhofen,
DE) ; Unger; Liliane; (Ludwigshafen, DE) ;
Sauer; Daryl R.; (Trevor, WI) ; Turner; Sean C.;
(Mannheim, DE) |
Correspondence
Address: |
WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
500 W. MADISON STREET
SUITE 3800
CHICAGO
IL
60661
US
|
Family ID: |
33131380 |
Appl. No.: |
10/552842 |
Filed: |
April 13, 2004 |
PCT Filed: |
April 13, 2004 |
PCT NO: |
PCT/EP04/03872 |
371 Date: |
August 22, 2006 |
Current U.S.
Class: |
514/252.02 ;
514/252.18; 514/253.01; 544/238; 544/295; 544/364 |
Current CPC
Class: |
A61P 25/16 20180101;
C07D 239/50 20130101; A61P 25/08 20180101; C07D 403/14 20130101;
A61P 25/32 20180101; C07D 213/76 20130101; A61P 15/10 20180101;
C07D 487/08 20130101; A61P 25/22 20180101; A61P 25/00 20180101;
A61P 25/36 20180101; A61P 15/00 20180101; C07D 213/74 20130101;
A61P 25/18 20180101; A61P 25/30 20180101; C07D 239/48 20130101;
C07D 403/04 20130101; A61P 13/12 20180101; A61P 43/00 20180101;
A61P 25/28 20180101; A61P 25/34 20180101; A61P 25/20 20180101; A61P
25/24 20180101 |
Class at
Publication: |
514/252.02 ;
544/238; 544/364; 544/295; 514/252.18; 514/253.01 |
International
Class: |
A61K 31/506 20070101
A61K031/506; A61K 31/501 20070101 A61K031/501; A61K 31/496 20070101
A61K031/496; C07D 403/14 20070101 C07D403/14; C07D 403/02 20070101
C07D403/02 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 14, 2003 |
US |
10413233 |
Claims
1. An N-[(piperazinyl)hetaryl]arylsulfonamide compound of the
general formula I ##STR24## in which R is oxygen, a group
N--R.sup.3 or a group CR.sup.3aR.sup.3b; Q is a bivalent,
6-membered heteroaromatic radical which possesses 1 or 2 N atoms as
ring members and which optionally carries one or two substituents
R.sup.a which is/are selected, independently of each other, from
halogen, CN, NO.sub.2, CO.sub.2R.sup.4, COR.sup.5,
C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-alkoxy,
C.sub.1--C.sub.4-haloalkyl, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7
and C.sub.1--C.sub.4-haloalkoxy; Ar is phenyl or a 6-membered
heteroaromatic radical which possesses 1 or 2 N atoms as ring
members and which optionally carries one or two substituents
R.sup.b, which is/are selected from halogen, NO.sub.2, CN,
CO.sub.2R.sup.4, COR.sup.5, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7,
C.sub.1--C.sub.6-alkyl, C.sub.1--C.sub.6-haloalkyl,
C.sub.1--C.sub.6-alkoxy, C.sub.1-C.sub.6s22-haloalkoxy,
C.sub.2--C.sub.6-alkenyl, C.sub.2--C.sub.6-alkynyl,
C.sub.3--C.sub.6-cycloalkyl, C.sub.3--C.sub.6-cycloalkoxy,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl and
C.sub.1--C.sub.4-haloalkyl, with it also being possible for two
radicals R.sup.b which are bonded to adjacent C atoms of Ar to be
together C.sub.3--C.sub.4-alkylene; n is 0, 1 or 2; R.sup.1 is
hydrogen, C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-haloalkyl,
C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-hydroxyalkyl,
C.sub.1--C.sub.4-alkoxy-C.sub.1--C.sub.4-alkyl,
C.sub.3-C.sub.4-alkenyl or C.sub.3--C.sub.4-alkynyl; R.sup.2 is
C.sub.1--C.sub.4-alkyl or, together with R.sup.1, is
C.sub.2--C.sub.5-alkylene or, in the case of n=2, the two radicals
R.sup.2 can together be C.sub.1--C.sub.4-alkylene; R.sup.3 is
hydrogen or C.sub.1--C.sub.4-alkyl; R.sup.3a, R.sup.3b are,
independently of each other, hydrogen or C.sub.1--C.sub.4-alkyl;
R.sup.4 is C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-haloalkyl,
C.sub.2--C.sub.4-alkenyl C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl, phenyl or
benzyl; and R.sup.5 is hydrogen, C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-haloalkyl, C.sub.2--C.sub.4-alkenyl
C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl, phenyl or
benzyl; R.sup.6, R.sup.7 are each independently selected from
C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-haloalkyl or together with
the nitrogen to which they are bound form a saturated 3-, 4-, 5- or
6-membered heterocycle, which additionally may comprise an oxygen
atom or an additional nitrogen atom as a ring member and which may
carry 1, 2, 3 or 4 C.sub.1--C.sub.4 alkyl groups; the N-oxides
thereof and the physiologically tolerated acid addition salts of
these compounds; with the exception of the compounds:
4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide
and
4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide.
2. The compound as claimed in claim 1, wherein R is N--R.sup.3 with
R.sup.3 being H or C.sub.1--C.sub.4-alkyl.
3. The compound as claimed in claim 2, wherein Q is a bivalent,
6-membered heteroaromatic radical which possesses 1 or 2 N atoms as
ring members and which optionally carries one or two substituents
R.sup.a which is/are selected, independently of each other, from
halogen, CN, NO.sub.2, CO.sub.2R.sup.4, COR.sup.5,
C.sub.1--C.sub.4-alkyl and C.sub.1--C.sub.4-haloalkyl and Ar is
phenyl or a 6-membered heteroaromatic radical which possesses 1 or
2N atoms as ring members and which optionally carries one or two
substituents R.sup.b, which is/are selected from halogen, NO.sub.2,
CN, CO.sub.2R.sup.4, COR.sup.5, C.sub.1--C.sub.6-alkyl,
C.sub.2--C.sub.6-alkenyl, C.sub.2--C.sub.6-alkynyl,
C.sub.3--C.sub.6-cycloalkyl, C.sub.3--C.sub.6-cycloalkyl-C\pard
plain.sub.1-C.sub.4-alkyl and C.sub.1--C.sub.4-haloalkyl, with it
also being possible for two radicals R.sup.b which are bonded to
adjacent C atoms of Ar to be together
C.sub.3--C.sub.4-alkylene.
4. The compound as claimed in claim 1, in which the piperazine ring
is bonded to the heteroaromatic radical Q in the para position in
relation to the group R--SO.sub.2--Ar.
5. The compound as claimed in claim 1, in which Q is a radical of
the formula ##STR25## in which A.sub.1, A.sub.2 and A.sub.3 are,
independently of each other, N or CH, one or two of the variables
A.sub.1, A.sub.2 and A.sub.3 can also be C--R.sup.a, k=0 or 1 and
R.sup.a is selected from halogen, C.sub.1-C.sub.4-alkyl,
C.sub.1--C.sub.4-haloalkyl, C.sub.1--C.sub.4-alkoxy, NH.sub.2,
NHR.sup.6, NR.sup.6R.sup.7s22 and C.sub.1--C.sub.4-haloalkoxy, with
A.sub.1, A.sub.2 and A.sub.3 not simultaneously being N or
simultaneously being selected from CH and C--R.sup.a.
6. The compound as claimed in claim 5, in which A.sub.3 is
nitrogen, A.sub.2 is CH and A.sub.1 is N or CH and wherein the
piperazine radical is located in the 2 position.
7. The compound as claimed in claim 6, in which Q is
pyridin-2,5-diyl which carries the piperazine radical in the 2
position.
8. The compound as claimed in claim 6, in which Q is a radical of
the formula ##STR26## in which A.sub.1 and A.sub.2 are,
independently of each other, N or CH and R.sup.a is selected from,
C.sub.1--C.sub.4-alkoxy, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7 and
C.sub.1--C.sub.4-haloalkoxy.
9. The compound as claimed in claim 8, in which A.sub.1 is N or CH
and A.sub.2 is CH and wherein the piperazine radical is located in
the 2 position.
10. The compound as claimed in claim 1, in which the radical Ar
carries a substituent R.sup.b in the para position and, where
appropriate, a further substituent R.sup.b in the meta position or
in the ortho position, in each case based on the binding site of
the sulfonamide group.
11. The compound as claimed in claim 1, in which Ar is phenyl or
pyridyl, which radicals possess, where appropriate, one or 2
R.sup.b substituents.
12. The compound as claimed in claim 1, in which R.sup.1 is
different from hydrogen and methyl.
13. The compound as claimed in claim 1 of the general formula Ia
##STR27## in which n, R.sup.1, R.sup.2, R.sup.3, R.sup.a and
R.sup.b have the meanings given in claim 1 and in which either
A.sub.1, A.sub.2 and A.sub.3 are, independently of each other, N or
CH and one or two of the variables A.sub.1, A.sub.2 and A.sub.3 can
also be C--R.sup.a, with Al, A.sub.2 and A.sub.3 not simultaneously
being N or simultaneously being selected from CH and C--R.sup.a, X
and Y are selected from CH, C--R.sup.b' and N, in which R.sup.b' is
halogen, methyl, CN, difluoromethyl or trifluoromethyl, with X and
Y not simultaneously being N or simultaneously being C--R.sup.b',
and k is O or 1.
14. The compound of the formula Ia as claimed in claim 13, in which
k=0, with A.sub.1, A.sub.2 and A.sub.3 being, independently of each
other, N or CH and A.sub.1, A.sub.2 and A.sub.3 not simultaneously
being N or simultaneously being CH.
15. The compound of the formula Ia as claimed in claim 14, in which
A.sub.1 is CH or N, A.sub.2 is CH and A.sub.3 is N.
16. The compound of the formula Ia as claimed in claim 13, in which
k is 1, A.sub.1 is CH or N, A.sub.2 is CH and A.sub.3 is N, and
R.sup.a is selected from, C.sub.1--C.sub.4-alkoxy, NH.sub.2,
NHR.sup.6, NR.sup.6R.sup.7 and C.sub.1--C.sub.4-haloalkoxy and
R.sup.a is bound to the carbon atom adjacent to A.sub.3.
17. The compound of the formula Ia as claimed in claim 13, in which
n is 0 or 1 and, in the case of n=1, R.sup.2 is bonded to the C
atom of the piperazine ring which is adjacent to the group
R.sup.1--N and is a methyl group having the S configuration.
18. The compound of the formula Ia as claimed claim 13, in which
the radical Ar carries a substituent R.sup.b in the para position
and, where appropriate, a further substituent R.sup.b in the meta
position or in the ortho position, in each case based on the
binding site of the sulfonamide group.
19. The compound of the formula Ia as claimed in claim 13, in which
Ar is phenyl or pyridyl, which radicals possess, where appropriate,
one or 2 R.sup.b substituents.
20. The compound of the -formula Ia as claimed in claim 13, in
which R.sup.1 is different from hydrogen and methyl.
21. The compound of the formula Ia as claimed in claim 13, of the
general formula Ia.1 ##STR28## in which n, X, Y, R.sup.1, R.sup.2,
R.sup.3, R.sup.a and R.sup.b have the meanings given in claim 13
and q is 0, 1 or 2.
22. The compound of the formula Ia as claimed in claim 13 of the
general formula Ia.2 ##STR29## in which n, X, Y, R.sup.1, R.sup.2,
R.sup.3, R.sup.a and R.sup.b have the meanings given in claim 13
and q is 0 or 1.
23. A pharmaceutical composition which comprises at least one
N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in
claim 1 and/or at least one physiologically tolerated acid addition
salt of I and/or an N-oxide of 1, where appropriate together with
physiologically acceptable carriers and/or auxiliary
substances.
24. The use of at least one N-[(piperazinyl)hetaryl]arylsulfonamide
compound of the formula I ##STR30## in which Q, Ar, n, R.sup.1,
R.sup.2 and R.sup.3 have the previously mentioned meanings, of the
N-oxides thereof and of the physiologically tolerated acid addition
salts thereof for producing a pharmaceutical composition for
treating diseases which respond to influencing by dopamine D.sub.3
receptor antagonists or dopamine D.sub.3 agonists.
25. The use as claimed in claim 24 for treating diseases of the
central nervous system.
26. The use as claimed in claim 24 for treating kidney function
disturbances.
27. A method for treating a medical disorder susceptible to
treatment with a dopamine D.sub.3 receptor antagonist or a dopamine
D.sub.3 agonist, said method comprising administering an effective
amount of at least one compound of the claim 1 ##STR31## to a
subject in need thereof.
28. The method as claimed in claim 27, wherein the medical disorder
is a disease of the central nervous system.
29. The method as claimed in claim 27 wherein the medical disorder
is a disturbance of kidney function.
Description
DESCRIPTION
[0001] The present invention relates to novel
N-[(piperazinyl)hetaryl]arylsulfonamide compounds. The compounds
possess valuable therapeutic properties and are suitable, in
particular, for treating diseases which respond to modulation of
the dopamine D.sub.3 receptor.
[0002] Neurons obtain their information by way of G protein-coupled
receptors, inter alia. A large number of substances exert their
effect by way of these receptors. One of them is dopamine.
Confirmed findings exist with regard to the presence of dopamine
and its physiological function as a neurotransmitter. Disturbances
in the dopaminergic transmitter system result in diseases of the
central nervous system which include, for example, schizophrenia,
depression and Parkinson's disease. These diseases, and others, are
treated with drugs which interact with the dopamine receptors.
[0003] Up until 1990, two subtypes of dopamine receptor had been
clearly defined pharmacologically, namely the D.sub.1 and D.sub.2
receptors. More recently, a third subtype was found, namely the
D.sub.3 receptor which appears to mediate some effects of
antipsychotics and antiparkinsonians (J. C. Schwartz et al., The
Dopamine D.sub.3 Receptor as a Target for Antipsychotics, in Novel
Antipsychotic Drugs, H. Y. Meltzer, Ed. Raven Press, New York 1992,
pages 135-144; M. Dooley et al., Drugs and Aging 1998, 12, 495-514,
J. N. Joyce, Pharmacology and Therapeutics 2001, 90, pp. 231-59
"The Dopamine D.sub.3 Receptor as a Therapeutic Target for
Antipsychotic and Antiparkinsonian Drugs").
[0004] Since then, the dopamine receptors have been divided into
two families. On the one hand, there is the D.sub.2 group,
consisting of D.sub.2, D.sub.3 and D.sub.4 receptors, and, on the
other hand, the D.sub.1 group, consisting of D.sub.1 and D.sub.5
receptors. Whereas D.sub.1 and D.sub.2 receptors are widely
distributed, D.sub.3 receptors appear to be expressed
regioselectively. Thus, these receptors are preferentially to be
found in the limbic system and the projection regions of the
mesolimbic dopamine system, especially in the nucleus accumbens,
but also in other regions, such as the amygdala. Because of this
comparatively regioselective expression, D.sub.3 receptors are
regarded as being a target having few side-effects and it is
assumed that while a selective D.sub.3 ligand would have the
properties of known antipsychotics, it would not have their
dopamine D.sub.2 receptor-mediated neurological side-effects (P.
Sokoloff et al., Localization and Function of the D.sub.3 Dopamine
Receptor, Arzneim. Forsch./Drug Res. 42(1), 224 (1992); P. Sokoloff
et al. Molecular Cloning and Characterization of a Novel Dopamine
Receptor (D.sub.3) as a Target for Neuroleptics, Nature, 347, 146
(1990)).
[0005] Compounds having an affinity for the dopamine D.sub.3
receptor have been described in the prior art on various occasions,
e.g. in WO 96/02519, WO 96/02520, WO 96/02249, WO 96/02246 and DE
10131543 and WO 99/02503. Some of these compounds possess high
affinities for the dopamine D.sub.3 receptor. They have therefore
been proposed as being suitable for treating diseases of the
central nervous system. Some of the compounds described in these
publications possess a piperazinylhetaryl structure.
[0006] The invention is based on the object of providing compounds
which act as selective dopamine D.sub.3 receptor ligands.
[0007] This object is achieved by means of
N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general
formula I ##STR2## in which [0008] R is oxygen, a group N--R.sup.3
or a group CR.sup.3aR.sup.3b; [0009] Q is a bivalent, 6-membered
heteroaromatic radical which possesses 1 or 2N atoms as ring
members and which optionally carries one or two substituents
R.sup.a which is/are selected, independently of each other, from
halogen, CN, NO.sub.2, CO.sub.2R.sup.4, COR.sup.5,
C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-all(oxy,
C.sub.1--C.sub.4-haloalkyl, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7
and C.sub.1--C.sub.4-haloalkoxy; [0010] Ar is phenyl or a
6-membered heteroaromatic radical which possesses 1 or 2N atoms as
ring members and which optionally carries one or two substituents
R.sup.b, which is/are selected from halogen, NO.sub.2, CN,
CO.sub.2R.sup.4, COR.sup.5, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7,
C.sub.1--C.sub.6-alkyl, C.sub.1--C.sub.6-haloalkyl,
C.sub.1--C.sub.6-alkoxy, C.sub.1--C.sub.6-haloalkoxy,
C.sub.2--C.sub.6-alkenyl, C.sub.2--C.sub.6-alkynyl,
C.sub.3--C.sub.6-cycloalkyl, C.sub.3--C.sub.6-cycloalkoxy,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl and
C.sub.1--C.sub.4-haloalkyl, with it also being possible for two
radicals R.sup.b which are bonded to adjacent C atoms of Ar to be
together C.sub.3--C.sub.4-alkylene; [0011] n is 0, 1 or 2; [0012]
R.sup.1 is hydrogen, C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-haloalkyl, C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-hydroxyalkyl,
C.sub.1--C.sub.4-alkoxy-C.sub.1--C.sub.4-alkyl,
C.sub.3--C.sub.4-alkenyl or C.sub.3--C.sub.4-alkynyl; [0013]
R.sup.2 is C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-haloalkyl or,
together with R.sup.1, is C.sub.2--C.sub.5-alkylene or, in the case
of n=2, the two radicals R.sup.2 can together be
C.sub.1--C.sub.4-alkylene; [0014] R.sup.3 is hydrogen or
C.sub.1--C.sub.4-alkyl; [0015] R.sup.3a, R.sup.3b are,
independently of each other, hydrogen or C.sub.1--C.sub.4-alkyl;
[0016] R.sup.4 is C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-haloalkyl, C.sub.2--C.sub.4-alkenyl
C.sub.3--C.sub.8-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl, phenyl or
benzyl; [0017] R.sup.5 is hydrogen, C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-haloalkyl, C.sub.2--C.sub.4-alkenyl
C.sub.3--C.sub.6-cycloalkyl,
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl, phenyl or
benzyl; and [0018] R.sup.6, R.sup.7 are each independently selected
from C.sub.1--C.sub.4-alkyl, C.sub.1--C.sub.4-haloalkyl or together
with the nitrogen to which they are bound form a saturated 3-, 4-,
5- or 6-membered heterocycle, which additionally may comprise an
oxygen atom or an additional nitrogen atom as a ring member and
which may carry 1, 2, 3 or 4 C.sub.1--C.sub.4 alkyl groups; the
N-oxides thereof and the physiologically tolerated acid addition
salts of these compounds.
[0019] These compounds have not previously been described, with the
exception of
4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide
and
4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide,
which are offered for sale by Ambinter, Paris, as test substances
for exploratory libraries.
[0020] The present invention therefore relates to
N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general
formula I, to their N-oxides and to their physiologically tolerated
acid addition salts, with the exception of the compounds
4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide
and
4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide.
[0021] The present invention also relates to the use of
N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general
formula I, of their N-oxides and of their acid addition salts for
producing a pharmaceutical composition for treating diseases which
respond to the influence of dopamine-D.sub.3 receptor antagonists
or agonists.
[0022] The diseases which respond to the influence of dopamine
D.sub.3 receptor antagonists or agonists include, in particular,
disturbances and diseases of the central nervous system, in
particular affective disturbances, neurotic disturbances, stress
disturbances and somatoform disturbances and psychoses, especially
schizophrenia and depression and, in addition, disturbances of
kidney function, in particular kidney function disturbances which
are caused by diabetes mellitus (see WO 00/67847).
[0023] According to the invention, at least one compound of the
general formula I having the meanings mentioned at the outset is
used for treating the abovementioned indications. Provided the
compounds of the formula I possess one or more centers of
asymmetry, it is also possible to use enantiomeric mixtures, in
particular racemates, diastereomeric mixtures and tautomeric
mixtures, preferably, however, the respective essentially pure
enantiomers, diastereomers and tautomers.
[0024] It is likewise possible to use physiologically tolerated
salts of the compounds of the formula I, especially acid addition
salts with physiologically tolerated acids. Examples of suitable
physiologically tolerated organic and inorganic acids are
hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric
acid, C.sub.1--C.sub.4-alkylsulfonic acids, such as methanesulfonic
acid, aromatic sulfonic acids, such as benzenesulfonic acid and
toluenesulfonic acid, oxalic acid, maleic acid, fumaric acid,
lactic acid, tartaric acid, adipic acid and benzoic acid. Other
utilizable acids are described in Fortschritte der
Arzneimittelforschung [Advances in drug research], Volume 10, pages
224 ff., Birkhauser Verlag, Basel and Stuttgart, 1966.
[0025] It is likewise possible to use N-oxides of the compounds of
the formula I. In the N-oxides of the compounds of the formula I,
one or more of the N atoms which is/are ring members, and in
particular ring members in the aromatic heterocycles Q and/or Ar,
are present as an N-oxide group. Preference is given to those
N-oxides of the formula I in which the ring nitrogen atoms in the
piperazine ring do not form any N-oxide group. Particularly
preferred N-oxides exhibit a N-oxide group on one or two of the
ring nitrogen atoms of Ar and/or Q.
[0026] Here and in that which follows, halogen is fluorine,
chlorine, bromine or iodine.
[0027] C.sub.n--C.sub.m-Alkyl (in radicals such as alkoxy,
alkoxyalkyl, alkylthio, alkylamino, dialkylamino etc., as well) is
a straight-chain or branched alkyl group having from n to m carbon
atoms, e.g. from 1 to 4 carbon atoms. Examples of an alkyl group
are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl,
iso-butyl, tert-butyl, n-pentyl, 2-pentyl, neopentyl, n-hexyl and
the like.
[0028] C.sub.1--C.sub.4-Haloalkyl (in radicals such as haloalkoxy,
haloalkoxyalkyl, haloalkylthio, etc., as well) is an alkyl group
having from 1 to 4 C atoms in which all or some, e.g. 1, 2, 3 or 4
of the hydrogen atoms, is/are replaced by halogen atoms, in
particular by chlorine or fluorine. Preferred haloalkyl is
C.sub.1--C.sub.2-fluoroalkyl or C.sub.1--C.sub.2-fluorochloroalkyl,
in particular CF.sub.3, CHF.sub.2, CF.sub.2Cl, CH.sub.2F, and
CH.sub.2CF.sub.3.
[0029] C.sub.1--C.sub.4-Hydroxyalkyl is a C.sub.1--C.sub.4-alkyl
group which possesses an OH group, such as 2-hydroxyethyl,
2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxybutyl, 3-hydroxybutyl,
2-methyl-2-hydroxypropyl etc.
[0030] C.sub.1--C.sub.4-Alkoxy-C.sub.1--C.sub.4-alkyl is a
C.sub.1--C.sub.4-alkyl group which carries a
C.sub.1--C.sub.4-alkoxy substituent, e.g. methoxymethyl,
ethoxymethyl, 2-methoxyethyl, 1-methoxyethyl, 2-ethoxyethyl,
1-ethoxyethyl, n-propoxymethyl, isopropoxymethyl, n-butoxymethyl,
(1-methylpropoxy)methyl, (2-methylpropoxy)methyl,
CHZOC(CH.sub.3).sub.3, 2-(methoxy)ethyl, 2-(ethoxy)ethyl,
2-(n-propoxy)ethyl, 2-(1-methylethoxy)ethyl, 2-(n-butoxy)ethyl,
2-(1-methylpropoxy)ethyl, 2-(2-methylpropoxy)ethyl,
2-(1',1-dimethylethoxy)ethyl, 2-(methoxy)propyl, 2-(ethoxy)propyl,
2-(n-propoxy)propyl, 2-(1-methylethoxy)propyl, 2-(n-butoxy)propyl,
2-(1-methylpropoxy)propyl, 2-(2-methylpropoxy)propyl,
2-(1,1-dimethylethoxy)propyl, 3-(methoxy)propyl, 3-(ethoxy)propyl,
3-(n-propoxy)propyl, 3-(1-methylethoxy)propyl, 3-(n-butoxy)propyl,
3-(1-methylpropoxy)propyl, 3-(2-methylpropoxy)propyl,
3-(1,1-dimethylethoxy)propyl, 2-(methoxy)butyl, 2-(ethoxy)butyl,
2-(n-propoxy)butyl, 2-(1-methylethoxy)butyl, 2-(n-butoxy)butyl,
2-(1-methylpropoxy)butyl, 2-(2-methylpropoxy)butyl,
2-(1,1-dimethylethoxy)butyl, 3-(methoxy)butyl, 3-(ethoxy)butyl,
3-(n-propoxy)butyl, 3-(1-methylethoxy)butyl, 3-(n-butoxy)butyl,
3-(1-methylpropoxy)butyl, 3-(2-methylpropoxy)butyl,
3-(1,1-dimethylethoxy)butyl, 4-(methoxy)butyl, 4-(ethoxy)butyl,
4-(n-propoxy)butyl, 4-(1-methylethoxy)butyl, 4-(n-butoxy)butyl,
4-(1-methylpropoxy)butyl, 4-(2-methylpropoxy)butyl or
4-(1,1-dimethylethoxy)butyl, preferably methoxymethyl,
ethoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, 2-(methoxy)propyl,
2-(ethoxy)propyl or 3-(methoxy)propyl, or 3-(ethoxy)propyl.
[0031] C.sub.3--C.sub.6-Cycloalkyl is a cycloaliphatic radical
having from 3 to 6 C atoms, such as cyclopropyl, cyclobutyl,
cyclopentyl and cyclohexyl.
[0032] C.sub.3--C.sub.6e-Cycloalkyl-C.sub.1--C.sub.4-alkyl is a
C.sub.1--C.sub.4-alkyl group which carries a
C.sub.3--C.sub.6-cycloalkyl radical, e.g. cyclopropylmethyl,
cyclobutylmethyl, cyclopentylmethyl, 1-cyclopropylethyl,
1-cyclobutylethyl, 1-cyclopentylethyl, 2-cyclopropylethyl,
2-cyclobutylethyl, 2-cyclopentylethyl, 1-cyclopropylpropyl,
1-cyclobutylpropyl, 1-cyclopentylpropyl, 2-cyclopropylpropyl,
2-cyclobutylpropyl, 2-cyclopentylpropyl, 3-cyclopropylpropyl,
3-cyclobutylpropyl, 3-cyclopentylpropyl,
1-cyclopropyl-1-methylethyl, 1-cyclopentyl-1-methylethyl,
1-cyclopentyl-1-methylethyl, 3-cyclohexylpropyl,
1-cyclohexyl-1-methylethyl, 1-cyclohexyl-1-methylethyl or
1-cyclohexyl-1-methylethyl.
[0033] C.sub.2--C.sub.4-Alkenyl (in radicals such as alkenyloxy as
well) is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5
or 6 Gatoms, e.g. vinyl, allyl(2-propen-1-yl), 1-propen-1-yl,
2-propen-2-yl, methallyl(2-methylprop-2-en-1-yl) and the like.
C.sub.3--C.sub.4-Alkenyl is, in particular, allyl,
1-methylprop-2-en-1-yl, 2-buten-1-yl, 3-buten-1-yl, methallyl,
2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl
or 2-ethylprop-2-en-1-yl.
[0034] C.sub.3--C.sub.6-Alkynyl (in radicals such as alkinyloxy as
well) is a hydrocarbon radical having 2, 3, 4, 5 or 6 C atoms which
possesses a triple bond, e.g. propargyl (2-propyn-1-yl),
1-methylprop-2-yn-1-yl, 2-butyn-1-yl, 3-butyn-1-yl, 2-pentyn-1-yl,
1-pentyn-3-yl, etc.
[0035] Examples of 6-membered heteroaromatic radicals which possess
1 or 2 nitrogen atoms as ring members are, in particular, 2-, 3- or
4-pyridinyl, 2-, 4- or 5-pyrimidinyl, 2-or 3-pyrazinyl and 3- or
4-pyridazinyl. Examples of bivalent, 6-membered heteroaromatic
radicals' which possess 1 or 2 nitrogen atoms as ring members are,
in particular, pyridin-2,4-diyl, pyridin-2,5-diyl,
pyridin-2,6-diyl, pyridin-3,5-diyl, pyrimidin-2,4-diyl,
pyrimidin-2,5-diyl, pyrimidin-4,6-diyl, pyrazin-2,5-diyl,
pyrazin-2,6-diyl, pyridazin-3,6-diyl and pyridazin-3,5-diyl.
[0036] With regard to using the compounds according to the
invention as dopamine D.sub.3 receptor ligands, preference is given
to those compounds of formula I in which the piperazin ring is
bonded to the heteroaromatic radical Q in the meta position or, in
particular, in the para position with respect to the group R.
[0037] In one embodiment the radical R.sup.a is selected from
halogen, CN, NO.sub.2, CO.sub.2R.sup.4, COR.sup.5,
C.sub.1--C.sub.4-alkyl and C.sub.1--C.sub.4-haloalkyl. Preferred
meanings of R.sup.4 and R.sup.5 are, independently of each other, H
or C.sub.1--C.sub.4-alkyl. In another embodiment R.sup.a is
selected from C.sub.1--C.sub.4-alkoxy, C.sub.1--C.sub.4-haloalkoxy,
NH.sub.2, NHR.sup.6 and NR.sup.6R.sup.7. In this embodiment
preferred meanings of R.sup.6 and R.sup.7 are independently of each
other methyl or ethyl.
[0038] The heteroaromatic radical Q may be unsubstituted or possess
a substituent R.sup.a which is selected from halogen,
C.sub.1--C.sub.4-alkyl and C.sub.1--C.sub.4-haloalkyl,
C.sub.1--C.sub.4-alkoxy, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7 and
C.sub.1--C.sub.4-haloalkoxy. In one embodiment the radical R.sup.a
is selected from halogen, C.sub.1--C.sub.4-alkyl and
C.sub.1--C.sub.4-haloalkyl. In another preferred embodiment R.sup.a
is selected from C.sub.1--C.sub.4-alkoxy,
C.sub.1--C.sub.4-haloalkoxy, NH.sub.2, NHR.sup.6 and
NR.sup.6R.sup.7 with specific preference given to methoxy,
NH.sub.2, methylamino, dimethylamino, ethylamine, diethylamino and
methylethyl amino.
[0039] In a very preferred embodiment, Q is unsubstituted.
[0040] In another very preferred embodiment, Q carries a radical
selected from C.sub.1--C.sub.4-haloalkoxy, C.sub.1--C.sub.4-alkoxy,
C.sub.1--C.sub.4-haloalkyl, C.sub.1--C.sub.4-alkyl, NH.sub.2,
NHR.sup.6 or NR.sup.6R.sup.7. and especially methoxy or methyl.
[0041] Preference is given to the variables Q, R.sup.1, R.sup.2,
R.sup.3 and Ar preferably having, independently of each other, the
meanings given below:
[0042] Q is preferably a radical of the formula A: ##STR3## in
which A.sub.1, A.sub.2 and A.sub.3 are, independently of each
other, N or CH, and one or two of the variables A.sub.1, A.sub.2
and A.sub.3 can also be C--R.sup.1, with A.sub.1, A.sub.2 and
A.sub.3 not simultaneously being N or being simultaneously selected
from CH and C--R.sup.a. In formula A, k is 0 or 1 and R.sup.a has
the previously mentioned meanings.
[0043] In formula A, R.sup.a is preferably selected from halogen,
especially chlorine or fluorine, C.sub.1--C.sub.4-alkyl, especially
methyl, and C.sub.1--C.sub.4-haloalkyl, especially trifluoromethyl,
C.sub.1--C.sub.4-alkoxy especially methoxy,
C.sub.1--C.sub.4-haloalkoxy, especially difluormethoxy or
trifluormethoxy, NH.sub.2, NHR.sup.6 especially methylamino or
ethylamino, and NR.sup.6R.sup.7, especially dimethylamino,
diethylamino or methylethylamino. The C atom which is located
between the atoms A.sub.1 and A.sub.3 preferably carries the
piperazinyl radical.
[0044] In particular, none of the variables A.sub.1, A.sub.2 and
A.sub.3 is C--R.sup.a. Preferred radicals Q are those of formula A,
in which A.sub.1 and/or A.sub.3 is/are N, the remaining variable
A.sub.1 or A.sub.2 is CH or C--R.sup.a, A.sub.2 is CH, and the
piperazinyl radical is bonded to the C atom which is located
between A.sub.1 and A.sub.3.
[0045] Preference is furthermore given to compounds of the formula
I, in which A.sub.1 and A.sub.2 in formula A are N and A.sub.3 is
CH or C--R.sup.a.
[0046] In a very preferred embodiment k in formula A is 0. In
particular, Q is pyridin-2,5-diyl or pyrimidin-2,5-diyl which are
unsubstituted or able to possess a substituent R.sup.a which is
different from hydrogen. The piperazinyl radical is then preferably
arranged in the 2 position.
[0047] In another very preferred embodiment k in formula A is 1,
A.sub.3 is N. Al and A.sub.2 are, independently of each other, N or
CH and R.sup.a is selected from C.sub.1--C.sub.4-alkoxy,
C.sub.1--C.sub.4-alkyl, NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7 and
C.sub.1--C.sub.4-haloalkoxy. In particular R.sup.a is methoxy or
methyl. Most preferably the piperazine radical is located in the 2
position. In this embodiment compounds are especially preferred, in
which Al is N or CH, in particular CH and A.sub.2 is CH.
[0048] Ar is preferably phenyl or pyridyl which, where appropriate,
possesses one or two of the abovementioned substituents R.sup.b.
With regard to using the compounds according to the invention as
dopamine D.sub.3 receptor ligands, preference is given to those
compounds of formula I in which Ar carries one substituent R.sup.b
in the para position and, where appropriate, a further substituent
R.sup.b in the ortho position or in the metaposition, in each case
related to the binding site for the sulfonamide group. The radicals
R.sup.b may be identical or different. Preference is given to the
radicals R.sup.b in the para position being selected from
C.sub.2--C.sub.6-alkyl, C.sub.2--C.sub.6-alkenyl,
C.sub.2--C.sub.6-alkynyl, C.sub.3--C.sub.6-cycloalkyl, NH.sub.2,
NHR.sup.6 and NR.sup.6R.sup.7.
[0049] In one preferred embodiment the radical R.sup.b in the para
position is selected from C.sub.2--C.sub.6-alkyl,
C.sub.2--C.sub.6-alkenyl, C.sub.2--C.sub.6-alkynyl,
C.sub.3--C.sub.6-cycloalkyl, in particular, from branched
C.sub.3--C.sub.6-alkyl, especially isopropyl, and
C.sub.3--C.sub.6-cycloalkyl, especially cyclopropyl. Very
particular preference is given to the radical R.sup.b which is
arranged in the para position of Ar being isopropyl.
[0050] In one preferred embodiment the radical R.sup.b in the para
position is selected from NHR.sup.6 and NR.sup.6R.sup.7. In this
embodiment preferred meanings of R.sup.6 and R.sup.7 are
independently of each other methyl or ethyl or form together with
the N atom a saturated 3-, 4-, 5- or 6-membered heterocycle, which
additionally may comprise an oxygen atom or an additional nitrogen
atom as a ring member and which may carry 1, 2, 3 or 4
C.sub.1--C.sub.4 alkyl groups, e.g. a radical from the group
consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl,
morpholinyl etc.
[0051] Preferred radicals R.sup.b in the meta position or ortho
position are selected from halogen, especially chlorine and
fluorine, C.sub.1--C.sub.4-alkyl, especially methyl, CN,
trifluoromethyl and difluoromethyl.
[0052] With regard to using the compounds according to the
invention as dopamine D.sub.3 receptor ligands, preference is given
to those compounds of the formula I in which R.sup.1 is different
from hydrogen, in particular hydrogen and methyl. In particular,
R.sup.1 is C.sub.2--C.sub.3-alkyl, cyclopropylmethyl or,
particularly preferably, ethyl, allyl or n-propyl.
[0053] The variable n is preferably 0 or 1. Provided n is .noteq.0,
R.sup.2 is preferably methyl. When n is .noteq.0, the group R.sup.2
is preferably bonded to a carbon atom in the piperazine ring which
is adjacent to the group R.sup.1--N. In particularly preferred
compounds, n=0. Particular preference is also given to compounds of
the formula I in which it applies that n=1 and R.sup.2 is a methyl
group which is bonded to a carbon atom in the piperazine ring which
is adjacent to the group R.sup.1--N. The compounds can then be
present as a racemate, as pure enantiomers or as nonracemic
mixtures of the enantiomers. Among these, particular preference is
given to those compounds in which the C atom which carries the
methyl group exhibits the S configuration.
[0054] R.sup.3 is preferably hydrogen or C.sub.1--C.sub.4-alkyl
and, in particular, hydrogen.
[0055] If R is a group CR.sup.3aR.sup.3b, at least one of the
radicals R.sup.3a or R.sup.3b is hydrogen. More preferably both
radicals R.sup.3a and R.sup.3b are hydrogen.
[0056] Among the compounds of the general formula I, preference is
given to the compounds I, wherein R is N--R.sup.3, wherein R.sup.3
is as defined above and especially H. Amongst these compounds
preference is given to the compounds of the general formula Ia
##STR4## in which n, R.sup.1, R.sup.2, R.sup.3, R.sup.a and R.sup.b
have the previously mentioned meanings, in particular the meanings
specified as being preferred, and in which A.sub.1, A.sub.2 and
A.sub.3 are, independently of each other, N or CH, and one of the
variables A.sub.1, A.sub.2 and A.sub.3 can also be C--R.sup.a, with
A.sub.1, A.sub.2 and A.sub.3 not simultaneously being N or
simultaneously being selected from CH and C--R.sup.a, and X and Y
are selected from CH, C--R.sup.b' and N, in which R.sup.b' is
halogen, methyl, CN, difluoromethyl or trifluoromethyl, with X and
Y not simultaneously being N or simultaneously being C--R.sup.b',
and k is 0 or 1. R.sup.a has the previously mentioned meanings. In
particular, R.sup.a is selected from halogen, especially chlorine
or fluorine, C.sub.1--C.sub.4-alkyl, especially methyl, and
C.sub.1--C.sub.4-haloalkyl, especially trifluoromethyl,
C.sub.0--C.sub.4-alkoxy especially methoxy,
C.sub.1--C.sub.4-haloalkoxy, especially difluormethoxy or
trifluormethoxy, NH.sub.2, NHR.sup.6 especially methylamino or
ethylamino, and NR.sup.6R.sup.7, especially dimethylamino,
diethylamino or methylethylamino.
[0057] In particular, none of the variables A.sup.1, A.sup.2 and
A.sup.3 is C--R.sup.a. Preferred compounds Ia are those in which
A.sub.1 and/or A.sub.3 is/are N, the remaining variable A.sub.1 or
A.sub.2 is CH or C--R.sup.a, A.sub.2 is CH.
[0058] In particular preferred embodiment, k=0. Among these,
preference is furthermore given to compound I in which A.sub.1 and
A.sub.2 are N and A.sub.3 is CH or C--R.sup.a. Among these,
preference is given to those compounds of the formula la in which X
or Y is CH or N and, in particular, both are CH.
[0059] In another very preferred embodiment k in formula Ia is 1,
A.sub.3 is N, A.sub.1 and A.sub.2 are, independently of each other,
N or CH and R.sup.a is selected from C.sub.1--C.sub.4-alkyl,
C.sub.1--C.sub.4-alkoxy, C.sub.1--C.sub.4-haloalkyl, NH.sub.2,
NHR.sup.6, NR.sup.6R.sup.7 and C.sub.1--C.sub.4-haloalkoxy. In
particular R.sup.a is methoxy or methyl. In this embodiment
compounds are especially preferred, in which A.sub.1 is N or CH, in
particular CH and A.sub.2 is CH.
[0060] Among the compounds of general formula Ia, preference is
given to the compounds of general formula Ia.1 ##STR5## in which n,
X, Y, R.sup.1, R.sup.2, R.sup.3, R.sup.a and R.sup.b have the
previously mentioned meanings, in particular the meanings specified
as being preferred, and q is 0, 1 or 2 and in particular 0 or 1. If
q is 1, the radical R.sup.a is preferably bound to the carbon atom
which is adjacent to the nitrogen atom of the pyridine ring
[0061] Among the compounds of general formula Ia, preference is
furthermore given to the compounds of general formula Ia.2 ##STR6##
in which n, X, Y, R.sup.1, R.sup.2, R.sup.3, R.sup.a and R.sup.b
have the previously mentioned meanings, in particular the meanings
specified as being preferred, and q and q' are independently of
each other 0 or 1, with q+q' preferably being 0 or 1.
[0062] Examples of compounds of the formula Ia.1 are the compounds
of the following general formulae Ia.1a, Ia.1b, Ia.1c, Ia.1d,
Ia.1e, Ia.1f, Ia.1g, Ia.1h and Ia.1k: ##STR7## ##STR8## in which
R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, X, Y and R.sup.b,
have the meanings specified in one line in Table 1.
[0063] Examples of compounds of the formula Ia.2 are the compounds
of the following general formulae Ia.2a, Ia.2b, Ia.2c, Ia.2d and
Ia.2e: ##STR9##
[0064] in which R.sup.1, R.sup.a, R.sup.2b, R.sup.2c, R.sup.3, X, Y
and R.sup.b have the meanings specified in one line in Table 1.
TABLE-US-00001 TABLE 1 No. R.sup.1 R.sup.2a R.sup.2b R.sup.2c
R.sup.3 X Y R.sup.b 1. H H H H H CH CH CH(CH.sub.3).sub.2 2.
CH.sub.3 H H H H CH CH CH(CH.sub.3).sub.2 3. CH.sub.2CH.sub.3 H H H
H CH CH CH(CH.sub.3).sub.2 4. CH.sub.2CH.dbd.CH.sub.2 H H H H CH CH
CH(CH.sub.3).sub.2 5. CH.sub.2-c-C.sub.3H.sub.5 H H H H CH CH
CH(CH.sub.3).sub.2 6. CH.sub.2CH.sub.2CH.sub.3 H H H H CH CH
CH(CH.sub.3).sub.2 7. H (s)CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2
8. CH.sub.3 (s)CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2 9.
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2 10.
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2
11. CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH CH
CH(CH.sub.3).sub.2 12. CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H
CH CH CH(CH.sub.3).sub.2 13. CH.sub.3 rac-CH.sub.3 H H H CH CH
CH(CH.sub.3).sub.2 14. CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H
CH CH CH(CH.sub.3).sub.2 15. CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3
H H H CH CH CH(CH.sub.3).sub.2 16. CH.sub.2CH.sub.2CH.sub.3
rac-CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2 17. CH.sub.3
(R)CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2 18.
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH CH CH(CH.sub.3).sub.2
19. CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH CH
CH(CH.sub.3).sub.2 20. CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
CH CH CH(CH.sub.3).sub.2 21. CH.sub.3 H CH.sub.3 H H CH CH
CH(CH.sub.3).sub.2 22. CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H CH CH
CH(CH.sub.3).sub.2 23. CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H CH
CH CH(CH.sub.3).sub.2 24. CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H H
CH CH CH(CH.sub.3).sub.2 25. CH.sub.3 CH.sub.3 H CH.sub.3 H CH CH
CH(CH.sub.3).sub.2 26. CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3
H CH CH CH(CH.sub.3).sub.2 27. CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H
CH.sub.3 H CH CH CH(CH.sub.3).sub.2 28. CH.sub.2CH.sub.2CH.sub.3
CH.sub.3 H CH.sub.3 H CH CH CH(CH.sub.3).sub.2 29. CH.sub.3
CH.sub.3 CH.sub.3 H H CH CH CH(CH.sub.3).sub.2 30.
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H H CH CH
CH(CH.sub.3).sub.2 31. CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3
H H CH CH CH(CH.sub.3).sub.2 32. CH.sub.2CH.sub.2CH.sub.3 CH.sub.3
CH.sub.3 H H CH CH CH(CH.sub.3).sub.2 33. (s)(CH.sub.2).sub.3 H H H
CH CH CH(CH.sub.3).sub.2 34. (s)(CH.sub.2).sub.4 H H H CH CH
CH(CH.sub.3).sub.2 35. rac(CH.sub.2).sub.3 H H H CH CH
CH(CH.sub.3).sub.2 36. rac (CH.sub.2).sub.4 H H H CH CH
CH(CH.sub.3).sub.2 37. (R)(CH.sub.2).sub.3 H H H CH CH
CH(CH.sub.3).sub.2 38. (R)(CH.sub.2).sub.4 H H H CH CH
CH(CH.sub.3).sub.2 39. CH.sub.2CH.dbd.CH.sub.2 H H H H C--Cl CH
CH(CH.sub.3).sub.2 40. CH.sub.2-c-C.sub.3H.sub.5 H H H H C--Cl CH
CH(CH.sub.3).sub.2 41. CH.sub.2CH.sub.2CH.sub.3 H H H H C--Cl CH
CH(CH.sub.3).sub.2 42. CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H
C--Cl CH CH(CH.sub.3).sub.2 43. CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H H C--Cl CH CH(CH.sub.3).sub.2 44. CH.sub.2CH.sub.3
(s)CH.sub.3 H H H C--Cl CH CH(CH.sub.3).sub.2 45.
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H C--Cl CH
CH(CH.sub.3).sub.2 46. CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H
C--Cl CH CH(CH.sub.3).sub.2 47. CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H H C--Cl CH CH(CH.sub.3).sub.2 48.
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H C--Cl CH
CH(CH.sub.3).sub.2 49. CH.sub.2CH.sub.3 rac-CH.sub.3 H H H C--Cl CH
CH(CH.sub.3).sub.2 50. CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H
C--Cl CH CH(CH.sub.3).sub.2 51. CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H H C--Cl CH CH(CH.sub.3).sub.2 52. CH.sub.2CH.sub.3
(R)CH.sub.3 H H H C--Cl CH CH(CH.sub.3).sub.2 53.
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H C--Cl CH
CH(CH.sub.3).sub.2 54. CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H C--Cl
CH CH(CH.sub.3).sub.2 55. CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H
C--Cl CH CH(CH.sub.3).sub.2 56. CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3
H H C--Cl CH CH(CH.sub.3).sub.2 57. CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 H CH.sub.3 H C--Cl CH CH(CH.sub.3).sub.2 58.
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 H C--Cl CH
CH(CH.sub.3).sub.2 59. CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3
H C--Cl CH CH(CH.sub.3).sub.2 60. CH.sub.2CH.dbd.CH.sub.2 CH.sub.3
CH.sub.3 H H C--Cl CH CH(CH.sub.3).sub.2 61.
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H H C--Cl CH
CH(CH.sub.3).sub.2 62. CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
H C--Cl CH CH(CH.sub.3).sub.2 63. (CH.sub.2).sub.3 H H H C--Cl CH
CH(CH.sub.3).sub.2 64. (CH.sub.2).sub.4 H H H C--Cl CH
CH(CH.sub.3).sub.2 65. CH.sub.2CH.dbd.CH.sub.2 H H H H CH C--Cl
CH(CH.sub.3).sub.2 66. CH.sub.2-c-C.sub.3H.sub.5 H H H H CH C--Cl
CH(CH.sub.3).sub.2 67. CH.sub.2CH.sub.2CH.sub.3 H H H H CH C--Cl
CH(CH.sub.3).sub.2 68. CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH
C--Cl CH(CH.sub.3).sub.2 69. CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3
H H H CH C--Cl CH(CH.sub.3).sub.2 70. CH.sub.2CH.sub.2CH.sub.3
(s)CH.sub.3 H H H CH C--Cl CH(CH.sub.3).sub.2 71. CH.sub.2CH.sub.3
(s)CH.sub.3 H H H CH C--Cl CH(CH.sub.3).sub.2 72.
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH C--Cl
CH(CH.sub.3).sub.2 73. CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H H
CH C--Cl CH(CH.sub.3).sub.2 74. CH.sub.2CH.sub.2CH.sub.3
rac-CH.sub.3 H H H CH C--Cl CH(CH.sub.3).sub.2 75. CH.sub.2CH.sub.3
rac-CH.sub.3 H H H CH C--Cl CH(CH.sub.3).sub.2 76.
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH C--Cl
CH(CH.sub.3).sub.2 77. CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H
CH C--Cl CH(CH.sub.3).sub.2 78. CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
CH C--Cl CH(CH.sub.3).sub.2 79. CH.sub.2CH.sub.2CH.sub.3
(R)CH.sub.3 H H H CH C--Cl CH(CH.sub.3).sub.2 80.
CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H CH C--Cl CH(CH.sub.3).sub.2
81. CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H CH C--Cl
CH(CH.sub.3).sub.2 82. CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H H CH
C--Cl CH(CH.sub.3).sub.2 83. CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H
CH.sub.3 H CH C--Cl CH(CH.sub.3).sub.2 84.
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 H CH C--Cl
CH(CH.sub.3).sub.2 85. CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3
H CH C--Cl CH(CH.sub.3).sub.2 86. CH.sub.2CH.dbd.CH.sub.2 CH.sub.3
CH.sub.3 H H CH C--Cl CH(CH.sub.3).sub.2 87.
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H H CH C--Cl
CH(CH.sub.3).sub.2 88. CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
H CH C--Cl CH(CH.sub.3).sub.2 89. (CH.sub.2).sub.3 H H H CH C--Cl
CH(CH.sub.3).sub.2 90. (CH.sub.2).sub.4 H H H CH C--Cl
CH(CH.sub.3).sub.2 91. CH.sub.2CH.dbd.CH.sub.2 H H H H C--CH.sub.3
CH CH(CH.sub.3).sub.2 92. CH.sub.2-c-C.sub.3H.sub.5 H H H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 93. CH.sub.2CH.sub.2CH.sub.3 H H
H H C--CH.sub.3 CH CH(CH.sub.3).sub.2 94. CH.sub.2CH.dbd.CH.sub.2
(s)CH.sub.3 H H H C--CH.sub.3 CH CH(CH.sub.3).sub.2 95.
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H C--CH.sub.3 CH
CH(CH.sub.3).sub.2 96. CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 97. CH.sub.2CH.dbd.CH.sub.2
rac-CH.sub.3 H H H C--CH.sub.3 CH CH(CH.sub.3).sub.2 98.
CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H H C--CH.sub.3 CH
CH(CH.sub.3).sub.2 99. CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 100 CH.sub.2CH.dbd.CH.sub.2
(R)CH.sub.3 H H H C--CH.sub.3 CH CH(CH.sub.3).sub.2 101
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H C--CH.sub.3 CH
CH(CH.sub.3).sub.2 102 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 103 CH.sub.2CH.dbd.CH.sub.2 H
CH.sub.3 H H C--CH.sub.3 CH CH(CH.sub.3).sub.2 104
CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H C--CH.sub.3 CH
CH(CH.sub.3).sub.2 105 CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 106 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 H CH.sub.3 H C--CH.sub.3 CH CH(CH.sub.3).sub.2 107
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 H C--CH.sub.3 CH
CH(CH.sub.3).sub.2 108 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3
H C--CH.sub.3 CH CH(CH.sub.3).sub.2 109 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 CH.sub.3 H H C--CH.sub.3 CH CH(CH.sub.3).sub.2 110
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H H C--CH.sub.3 CH
CH(CH.sub.3).sub.2 111 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
H C--CH.sub.3 CH CH(CH.sub.3).sub.2 112 (CH.sub.2).sub.3 H H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 113 (CH.sub.2).sub.4 H H H
C--CH.sub.3 CH CH(CH.sub.3).sub.2 114 CH.sub.2CH.dbd.CH.sub.2 H H H
H CH C--CH.sub.3 CH(CH.sub.3).sub.2 115 CH.sub.2-c-C.sub.3H.sub.5 H
H H H CH C--CH.sub.3 CH(CH.sub.3).sub.2 116
CH.sub.2CH.sub.2CH.sub.3 H H H H CH C--CH.sub.3 CH(CH.sub.3).sub.2
117 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 118 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H
CH C--CH.sub.3 CH(CH.sub.3).sub.2 119 CH.sub.2CH.sub.2CH.sub.3
(s)CH.sub.3 H H H CH C--CH.sub.3 CH(CH.sub.3).sub.2 120
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 121 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H H
CH C--CH.sub.3 CH(CH.sub.3).sub.2 122 CH.sub.2CH.sub.2CH.sub.3
rac-CH.sub.3 H H H CH C--CH.sub.3 CH(CH.sub.3).sub.2 123
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 124 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H
CH C--CH.sub.3 CH(CH.sub.3).sub.2 125 CH.sub.2CH.sub.2CH.sub.3
(T)CH.sub.3 H H H CH C--CH.sub.3 CH(CH.sub.3).sub.2 126
CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 127 CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H CH
C--CH.sub.3 CH(CH.sub.3).sub.2 128 CH.sub.2CH.sub.2CH.sub.3 H
CH.sub.3 H H CH C--CH.sub.3 CH(CH.sub.3).sub.2 129
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3 H CH C--CH.sub.3
CH(CH.sub.3).sub.2 130 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H
CH.sub.3 H CH C--CH.sub.3 CH(CH.sub.3).sub.2 131
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3 H CH C--CH.sub.3
CH(CH.sub.3).sub.2 132 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H
H CH C--CH.sub.3 CH(CH.sub.3).sub.2 133 CH.sub.2-c-C.sub.3H.sub.5
CH.sub.3 CH.sub.3 H H CH C--CH.sub.3 CH(CH.sub.3).sub.2 134
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 135 (CH.sub.2).sub.3 H H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 136 (CH.sub.2).sub.4 H H H CH C--CH.sub.3
CH(CH.sub.3).sub.2 137 H H H H H CH CH c-C.sub.3H.sub.5 138
CH.sub.3 H H H H CH CH c-C.sub.3H.sub.5 139 CH.sub.2CH.sub.3 H H H
H CH CH c-C.sub.3H.sub.5 140 CH.sub.2CH.dbd.CH.sub.2 H H H H CH CH
c-C.sub.3H.sub.5 141 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH CH
c-C.sub.3H.sub.5 142 CH.sub.2CH.sub.2CH.sub.3 H H H H CH CH
c-C.sub.3H.sub.5 143 H (s)CH.sub.3 H H H CH CH c-C.sub.3H.sub.5 144
CH.sub.3 (s)CH.sub.3 H H H CH CH c-C.sub.3H.sub.5 145
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH CH c-C.sub.3H.sub.5 146
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH CH c-C.sub.3H.sub.5
147 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH CH
c-C.sub.3H.sub.5 148 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH
CH c-C.sub.3H.sub.5 149 CH.sub.3 rac-CH.sub.3 H H H CH CH
c-C.sub.3H.sub.5 150 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH
CH c-C.sub.3H.sub.5 151 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H
H CH CH c-C.sub.3H.sub.5 152 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3
H H H CH CH c-C.sub.3H.sub.5 153 CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
CH CH c-C.sub.3H.sub.5 154 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
H CH CH c-C.sub.3H.sub.5 155 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3
H H H CH CH c-C.sub.3H.sub.5 156 CH.sub.2CH.sub.2CH.sub.3
(R)CH.sub.3 H H H CH CH c-C.sub.3H.sub.5 157 CH.sub.3 H CH.sub.3 H
H CH CH c-C.sub.3H.sub.5 158 CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H
CH CH c-C.sub.3H.sub.5 159 CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H
CH CH c-C.sub.3H.sub.5 160 CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H H
CH CH c-C.sub.3H.sub.5 161 CH.sub.3 CH.sub.3 H CH.sub.3 H CH CH
c-C.sub.3H.sub.5 162 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3 H
CH CH c-C.sub.3H.sub.5 163 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H
CH.sub.3 H CH CH c-C.sub.3H.sub.5 164 CH.sub.2CH.sub.2CH.sub.3
CH.sub.3 H CH.sub.3 H CH CH c-C.sub.3H.sub.5 165 CH.sub.3 CH.sub.3
CH.sub.3 H H CH CH c-C.sub.3H.sub.5 166 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 CH.sub.3 H H CH CH c-C.sub.3H.sub.5 167
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H H CH CH
c-C.sub.3H.sub.5 168 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H H
CH CH c-C.sub.3H.sub.5 169 (s)(CH.sub.2).sub.3 H H H CH CH
c-C.sub.3H.sub.5 170 (s)(CH.sub.2).sub.4 H H H CH CH
c-C.sub.3H.sub.5 171 rac(CH.sub.2).sub.3 H H H CH CH
c-C.sub.3H.sub.5 172 rac(CH.sub.2).sub.4 H H H CH CH
c-C.sub.3H.sub.5
173 (R)(CH.sub.2).sub.3 H H H CH CH c-C.sub.3H.sub.5 174
(R)(CH.sub.2).sub.4 H H H CH CH c-C.sub.3H.sub.5 175
CH.sub.2CH.dbd.CH.sub.2 H H H H CH C--Cl c-C.sub.3H.sub.5 176
CH.sub.2-c-C.sub.3H.sub.5 H H H H CH C--Cl c-C.sub.3H.sub.5 177
CH.sub.2CH.sub.2CH.sub.3 H H H H CH C--Cl c-C.sub.3H.sub.5 178
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH C--Cl c-C.sub.3H.sub.5
179 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH C--Cl
c-C.sub.3H.sub.5 180 CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH C--Cl
c-C.sub.3H.sub.5 181 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH
C--Cl c-C.sub.3H.sub.5 182 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
H CH C--Cl c-C.sub.3H.sub.5 183 CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H H CH C--Cl c-C.sub.3H.sub.5 184 CH.sub.2CH.sub.3
rac-CH.sub.3 H H H CH C--Cl c-C.sub.3H.sub.5 185
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH C--Cl
c-C.sub.3H.sub.5 186 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH
C--Cl c-C.sub.3H.sub.5 187 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H
H H CH C--Cl c-C.sub.3H.sub.5 188 CH.sub.2CH.sub.3 (R)CH.sub.3 H H
H CH C--Cl c-C.sub.3H.sub.5 189 CH.sub.2CH.sub.2CH.sub.3
(R)CH.sub.3 H H H CH C--Cl c-C.sub.3H.sub.5 190
CH.sub.2CH.dbd.CH.sub.2 H H H H CH C--CH.sub.3 c-C.sub.3H.sub.5 191
CH.sub.2-c-C.sub.3H.sub.5 H H H H CH C--CH.sub.3 c-C.sub.3H.sub.5
192 CH.sub.2CH.sub.2CH.sub.3 H H H H CH C--CH.sub.3
c-C.sub.3H.sub.5 193 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH
C--CH.sub.3 c-C.sub.3H.sub.5 194 CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H H CH C--CH.sub.3 c-C.sub.3H.sub.5 195
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH C--CH.sub.3 c-C.sub.3H.sub.5
196 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH C--CH.sub.3
c-C.sub.3H.sub.5 197 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH
C--CH.sub.3 c-C.sub.3H.sub.5 198 CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H H CH C--CH.sub.3 c-C.sub.3H.sub.5 199
CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH C--CH.sub.3 c-C.sub.3H.sub.5
200 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH C--CH.sub.3
c-C.sub.3H.sub.5 201 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH
C--CH.sub.3 c-C.sub.3H.sub.5 202 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H H CH C--CH.sub.3 c-C.sub.3H.sub.5 203
CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH C--CH.sub.3 c-C.sub.3H.sub.5
204 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH C--CH.sub.3
c-C.sub.3H.sub.5 205 CH.sub.2CH.dbd.CH.sub.2 H H H H C--Cl CH
c-C.sub.3H.sub.5 206 CH.sub.2-c-C.sub.3H.sub.5 H H H H C--Cl CH
c-C.sub.3H.sub.5 207 CH.sub.2CH.sub.2CH.sub.3 H H H H C--Cl CH
c-C.sub.3H.sub.5 208 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H
C--Cl CH c-C.sub.3H.sub.5 209 CH.sub.2-c-C.sub.3H.sub.5 (S)CH.sub.3
H H H C--Cl CH c-C.sub.3H.sub.5 210 CH.sub.2CH.sub.2CH.sub.3
(s)CH.sub.3 H H H C--Cl CH c-C.sub.3H.sub.5 211
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H C--Cl CH
c-C.sub.3H.sub.5 212 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H H
C--Cl CH c-C.sub.3H.sub.5 213 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3
H H H C--Cl CH c-C.sub.3H.sub.5 214 CH.sub.2CH.dbd.CH.sub.2 H H H H
C--CH.sub.3 CH c-C.sub.3H.sub.5 215 CH.sub.2-c-C.sub.3H.sub.5 H H H
H C--CH.sub.3 CH c-C.sub.3H.sub.5 216 CH.sub.2CH.sub.2CH.sub.3 H H
H H C--CH.sub.3 CH c-C.sub.3H.sub.5 217 CH.sub.2CH.dbd.CH.sub.2
(S)CH.sub.3 H H H C--CH.sub.3 CH c-C.sub.3H.sub.5 218
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H C--CH.sub.3 CH
c-C.sub.3H.sub.5 219 CH.sub.2CH.sub.3 (s)CH.sub.3 H H H C--CH.sub.3
CH c-C.sub.3H.sub.5 220 CH.sub.2CH.sub.2CH.sub.3 (S)CH.sub.3 H H H
C--CH.sub.3 CH c-C.sub.3H.sub.5 221 CH.sub.2CH.dbd.CH.sub.2
rac-CH.sub.3 H H H C--CH.sub.3 CH c-C.sub.3H.sub.5 222
CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H H C--CH.sub.3 CH
c-C.sub.3H.sub.5 223 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H
C--CH.sub.3 CH c-C.sub.3H.sub.5 224 CH.sub.2CH.dbd.CH.sub.2
(R)CH.sub.3 H H H C--CH.sub.3 CH c-C.sub.3H.sub.5 225
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H C--CH.sub.3 CH
c-C.sub.3H.sub.5 226 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
C--CH.sub.3 CH c-C.sub.3H.sub.5 227 H H H H H CH CH C.sub.2H.sub.5
228 CH.sub.3 H H H H CH CH C.sub.2H.sub.5 229 CH.sub.2CH.sub.3 H H
H H CH CH C.sub.2H.sub.5 230 CH.sub.2CH.dbd.CH.sub.2 H H H H CH CH
C.sub.2H.sub.5 231 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH CH
C.sub.2H.sub.5 232 CH.sub.2CH.sub.2CH.sub.3 H H H H CH CH
C.sub.2H.sub.5 233 H (s)CH.sub.3 H H H CH CH C.sub.2H.sub.5 234
CH.sub.3 (s)CH.sub.3 H H H CH CH C.sub.2H.sub.5 235
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH CH C.sub.2H.sub.5 236
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH CH C.sub.2H.sub.5 237
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH CH C.sub.2H.sub.5
238 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH CH C.sub.2H.sub.5
239 CH.sub.3 rac-CH.sub.3 H H H CH CH C.sub.2H.sub.5 240
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH CH C.sub.2H.sub.5 241
CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H H CH CH C.sub.2H.sub.5
242 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH CH
C.sub.2H.sub.5 243 CH.sub.3 (R)CH.sub.3 H H H CH CH C.sub.2H.sub.5
244 CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH CH C.sub.2H.sub.5 245
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH CH C.sub.2H.sub.5 246
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH CH C.sub.2H.sub.5
247 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH CH C.sub.2H.sub.5
248 CH.sub.3 H CH.sub.3 H H CH CH C.sub.2H.sub.5 249
CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H CH CH C.sub.2H.sub.5 250
CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H H CH CH C.sub.2H.sub.5 251
CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H H CH CH C.sub.2H.sub.5 252
CH.sub.3 CH.sub.3 H CH.sub.3 H CH CH C.sub.2H.sub.5 253
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3 H CH CH C.sub.2H.sub.5
254 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 H CH CH
C.sub.2H.sub.5 255 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3 H
CH CH C.sub.2H.sub.5 256 CH.sub.3 CH.sub.3 CH.sub.3 H H CH CH
C.sub.2H.sub.5 257 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H H CH
CH C.sub.2H.sub.5 258 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H
H CH CH C.sub.2H.sub.5 259 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3
CH.sub.3 H H CH CH C.sub.2H.sub.5 260 (s)(CH.sub.2).sub.3 H H H CH
CH C.sub.2H.sub.5 261 (s)(CH.sub.2).sub.4 H H H CH CH
C.sub.2H.sub.5 262 rac(CH.sub.2).sub.3 H H H CH CH C.sub.2H.sub.5
263 rac(CH.sub.2).sub.4 H H H CH CH C.sub.2H.sub.5 264
(R)(CH.sub.2).sub.3 H H H CH CH C.sub.2H.sub.5 265
(R)(CH.sub.2).sub.4 H H H CH CH C.sub.2H.sub.5 266 H H H H H CH CH
CH.sub.3 267 CH.sub.3 H H H H CH CH CH.sub.3 268 CH.sub.2CH.sub.3 H
H H H CH CH CH.sub.3 269 CH.sub.2CH.dbd.CH.sub.2 H H H H CH CH
CH.sub.3 270 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH CH CH.sub.3 271
CH.sub.2CH.sub.2CH.sub.3 H H H H CH CH CH.sub.3 272 H (s)CH.sub.3 H
H H CH CH CH.sub.3 273 CH.sub.3 (s)CH.sub.3 H H H CH CH CH.sub.3
274 CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH CH CH.sub.3 275
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH CH CH.sub.3 276
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH CH CH.sub.3 277
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH CH CH.sub.3 278
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH CH CH.sub.3 279
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH CH CH.sub.3 280
CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH CH CH.sub.3 281
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH CH CH.sub.3 282
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH CH CH.sub.3 283
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH CH CH.sub.3 284
CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H H CH CH CH.sub.3 285
CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H H CH CH CH.sub.3 286
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3 H CH CH CH.sub.3 287
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3 H CH CH CH.sub.3 288
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H H CH CH CH.sub.3 289
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H H CH CH CH.sub.3 290
(s)(CH.sub.2).sub.3 H H H CH CH CH.sub.3 291 (s)(CH.sub.2).sub.4 H
H H CH CH CH.sub.3 292 rac(CH.sub.2).sub.3 H H H CH CH CH.sub.3 293
rac(CH.sub.2).sub.4 H H H CH CH CH.sub.3 294 (R)(CH.sub.2).sub.3 H
H H CH CH CH.sub.3 295 (R)(CH.sub.2).sub.4 H H H CH CH CH.sub.3 296
H H H H H N CH CH(CH.sub.3).sub.2 297 CH.sub.3 H H H H N CH
CH(CH.sub.3).sub.2 298 CH.sub.2CH.sub.3 H H H H N CH
CH(CH.sub.3).sub.2 299 CH.sub.2CH.dbd.CH.sub.2 H H H H N CH
CH(CH.sub.3).sub.2 300 CH.sub.2-c-C.sub.3H.sub.5 H H H H N CH
CH(CH.sub.3).sub.2 301 CH.sub.2CH.sub.2CH.sub.3 H H H H N CH
CH(CH.sub.3).sub.2 302 H (s)CH.sub.3 H H H N CH CH(CH.sub.3).sub.2
303 CH.sub.3 (s)CH.sub.3 H H H N CH CH(CH.sub.3).sub.2 304
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH CH(CH.sub.3).sub.2 305
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H N CH CH(CH.sub.3).sub.2
306 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H N CH
CH(CH.sub.3).sub.2 307 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N
CH CH(CH.sub.3).sub.2 308 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
H N CH CH(CH.sub.3).sub.2 309 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3
H H H N CH CH(CH.sub.3).sub.2 310 CH.sub.2CH.sub.3 (R)CH.sub.3 H H
H N CH CH(CH.sub.3).sub.2 311 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H
H H N CH CH(CH.sub.3).sub.2 312 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H H N CH CH(CH.sub.3).sub.2 313
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H N CH CH(CH.sub.3).sub.2
314 (s)(CH.sub.2).sub.3 H H H N CH CH(CH.sub.3).sub.2 315
(s)(CH.sub.2).sub.4 H H H N CH CH(CH.sub.3).sub.2 316
rac(CH.sub.2).sub.3 H H H N CH CH(CH.sub.3).sub.2 317
rac(CH.sub.2).sub.4 H H H N CH CH(CH.sub.3).sub.2 318
(R)(CH.sub.2).sub.3 H H H N CH CH(CH.sub.3).sub.2 319
(R)(CH.sub.2).sub.4 H H H N CH CH(CH.sub.3).sub.2 320 H H H H H N
CH CH.dbd.CH.sub.2 321 CH.sub.3 H H H H N CH CH.dbd.CH.sub.2 322
CH.sub.2CH.sub.3 H H H H N CH CH.dbd.CH.sub.2 323
CH.sub.2CH.dbd.CH.sub.2 H H H H N CH CH.dbd.CH.sub.2 324
CH.sub.2-c-C.sub.3H.sub.5 H H H H N CH CH.dbd.CH.sub.2 325
CH.sub.2CH.sub.2CH.sub.3 H H H H N CH CH.dbd.CH.sub.2 326 H
(s)CH.sub.3 H H H N CH CH.dbd.CH.sub.2 327 CH.sub.3 (s)CH.sub.3 H H
H N CH CH.dbd.CH.sub.2 328 CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH
CH.dbd.CH.sub.2 329 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H N CH
CH.dbd.CH.sub.2 330 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H N
CH CH.dbd.CH.sub.2 331 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N
CH CH.dbd.CH.sub.2 332 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H N
CH CH.dbd.CH.sub.2 333 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H N
CH CH.dbd.CH.sub.2 334 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H N
CH CH.dbd.CH.sub.2 335 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H
N CH CH.dbd.CH.sub.2 336 H H H H H N CH c-C.sub.3H.sub.5 337
CH.sub.3 H H H H N CH c-C.sub.3H.sub.5 338 CH.sub.2CH.sub.3 H H H H
N CH c-C.sub.3H.sub.5 339 CH.sub.2CH.dbd.CH.sub.2 H H H H N CH
c-C.sub.3H.sub.5 340 CH.sub.2-c-C.sub.3H.sub.5 H H H H N CH
c-C.sub.3H.sub.5 341 CH.sub.2CH.sub.2CH.sub.3 H H H H N CH
c-C.sub.3H.sub.5 342 H (s)CH.sub.3 H H H N CH c-C.sub.3H.sub.5 343
CH.sub.3 (s)CH.sub.3 H H H N CH c-C.sub.3H.sub.5 344
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH c-C.sub.3H.sub.5 345
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H N CH c-C.sub.3H.sub.5 346
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H N CH c-C.sub.3H.sub.5
347 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH
c-C.sub.3H.sub.5 348 CH.sub.2CH.sub.3 (R)CH.sub.3 H H H N CH
c-C.sub.3H.sub.5 349 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H N CH
c-C.sub.3H.sub.5 350 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H N
CH c-C.sub.3H.sub.5 351 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H
N CH c-C.sub.3H.sub.5 352 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H
H N CH c-C.sub.3H.sub.5 353 H H H H H N CH CH.sub.3 354 CH.sub.3 H
H H H N CH CH.sub.3 355 CH.sub.2CH.sub.3 H H H H N CH CH.sub.3 356
CH.sub.2CH.dbd.CH.sub.2 H H H H N CH CH.sub.3 357
CH.sub.2-c-C.sub.3H.sub.5 H H H H N CH CH.sub.3 358
CH.sub.2CH.sub.2CH.sub.3 H H H H N CH CH.sub.3 359 H (s)CH.sub.3 H
H H N CH CH.sub.3 360 CH.sub.3 (s)CH.sub.3 H H H N CH CH.sub.3 361
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH CH.sub.3 362
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H N CH CH.sub.3 363
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H N CH CH.sub.3 364
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH CH.sub.3 365
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H N CH CH.sub.3 366
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H N CH CH.sub.3 367
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H N CH CH.sub.3 368
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H N CH CH.sub.3 369 H H H
H H N CH CF.sub.3 370 CH.sub.3 H H H H N CH CF.sub.3 371
CH.sub.2CH.sub.3 H H H H N CH CF.sub.3 372 CH.sub.2CH.dbd.CH.sub.2
H H H H N CH CF.sub.3 373 CH.sub.2-c-C.sub.3H.sub.5 H H H H N CH
CF.sub.3 374 CH.sub.2CH.sub.2CH.sub.3 H H H H N CH CF.sub.3 375 H
(s)CH.sub.3 H H H N CH CF.sub.3 376 CH.sub.3 (s)CH.sub.3 H H H N CH
CF.sub.3 377 CH.sub.2CH.sub.3 H H H N CH CF.sub.3 378
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H N CH CF.sub.3 379
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H N CH CF.sub.3 380
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H N CH CF.sub.3 381
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H N CH CF.sub.3 382
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H N CH CF.sub.3 383
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H N CH CF.sub.3 384
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H N CH CF.sub.3 385 H H H
H H CH N CH(CH.sub.3).sub.2 386 CH.sub.3 H H H H CH N
CH(CH.sub.3).sub.2 387 CH.sub.2CH.sub.3 H H H H CH N
CH(CH.sub.3).sub.2 388 CH.sub.2CH.dbd.CH.sub.2 H H H H CH N
CH(CH.sub.3).sub.2 389 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH N
CH(CH.sub.3).sub.2 390 CH.sub.2CH.sub.2CH.sub.3 H H H H CH N
CH(CH.sub.3).sub.2 391 H (s)CH.sub.3 H H H CH N CH(CH.sub.3).sub.2
392 CH.sub.3 (s)CH.sub.3 H H H CH N CH(CH.sub.3).sub.2 393
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CH(CH.sub.3).sub.2 394
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH N CH(CH.sub.3).sub.2
395 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH N
CH(CH.sub.3).sub.2 396 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H
CH N CH(CH.sub.3).sub.2 397 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H
H H CH N CH(CH.sub.3).sub.2 398 CH.sub.2CH.sub.2CH.sub.3
rac-CH.sub.3 H H H CH N CH(CH.sub.3).sub.2 399 CH.sub.2CH.sub.3
(R)CH.sub.3 H H H CH N CH(CH.sub.3).sub.2 400
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH N CH(CH.sub.3).sub.2
401 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH N
CH(CH.sub.3).sub.2 402 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
CH N CH(CH.sub.3).sub.2 403 H H H H H CH N CH.dbd.CH.sub.2
404 CH.sub.3 H H H H CH N CH.dbd.CH.sub.2 405 CH.sub.2CH.sub.3 H H
H H CH N CH.dbd.CH.sub.2 406 CH.sub.2CH.dbd.CH.sub.2 H H H H CH N
CH.dbd.CH.sub.2 407 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH N
CH.dbd.CH.sub.2 408 CH.sub.2CH.sub.2CH.sub.3 H H H H CH N
CH.dbd.CH.sub.2 409 H (s)CH.sub.3 H H H CH N CH.dbd.CH.sub.2 410
CH.sub.3 (s)CH.sub.3 H H H CH N CH.dbd.CH.sub.2 411
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CH.dbd.CH.sub.2 412
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH N CH.dbd.CH.sub.2 413
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH N CH.dbd.CH.sub.2
414 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CH.dbd.CH.sub.2
415 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH N CH.dbd.CH.sub.2
416 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH N
CH.dbd.CH.sub.2 417 CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH N
CH.dbd.CH.sub.2 418 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH N
CH.dbd.CH.sub.2 419 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH
N CH.dbd.CH.sub.2 420 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH
N CH.dbd.CH.sub.2 421 H H H H H CH N c-C.sub.3H.sub.5 422 CH.sub.3
H H H H CH N c-C.sub.3H.sub.5 423 CH.sub.2CH.sub.3 H H H H CH N
c-C.sub.3H.sub.5 424 CH.sub.2CH.dbd.CH.sub.2 H H H H CH N
c-C.sub.3H.sub.5 425 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH N
c-C.sub.3H.sub.5 426 CH.sub.2CH.sub.2CH.sub.3 H H H H CH N
c-C.sub.3H.sub.5 427 H (s)CH.sub.3 H H H CH N c-C.sub.3H.sub.5 428
CH.sub.3 (s)CH.sub.3 H H H CH N c-C.sub.3H.sub.5 429
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N c-C.sub.3H.sub.5 430
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH N c-C.sub.3H.sub.5 431
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH N c-C.sub.3H.sub.5
432 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N
c-C.sub.3H.sub.5 433 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH
N c-C.sub.3H.sub.5 434 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H
CH N c-C.sub.3H.sub.5 435 CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH N
c-C.sub.3H.sub.5 436 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH N
c-C.sub.3H.sub.5 437 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH
N c-C.sub.3H.sub.5 438 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H
CH N c-C.sub.3H.sub.5 439 H H H H H CH N CH.sub.3 440 CH.sub.3 H H
H H CH N CH.sub.3 441 CH.sub.2CH.sub.3 H H H H CH N CH.sub.3 442
CH.sub.2CH.dbd.CH.sub.2 H H H H CH N CH.sub.3 443
CH.sub.2-c-C.sub.3H.sub.5 H H H H CH N CH.sub.3 444
CH.sub.2CH.sub.2CH.sub.3 H H H H CH N CH.sub.3 445 H (s)CH.sub.3 H
H H CH N CH.sub.3 446 CH.sub.3 (s)CH.sub.3 H H H CH N CH.sub.3 447
CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CH.sub.3 448
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH N CH.sub.3 449
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH N CH.sub.3 450
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CH.sub.3 451
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH N CH.sub.3 452
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH N CH.sub.3 453
CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH N CH.sub.3 454
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH N CH.sub.3 455
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH N CH.sub.3 456
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH N CH.sub.3 457 H H H
H H CH N CF.sub.3 458 CH.sub.3 H H H H CH N CF.sub.3 459
CH.sub.2CH.sub.3 H H H H CH N CF.sub.3 460 CH.sub.2CH.dbd.CH.sub.2
H H H H CH N CF.sub.3 461 CH.sub.2-c-C.sub.3H.sub.5 H H H H CH N
CF.sub.3 462 CH.sub.2CH.sub.2CH.sub.3 H H H H CH N CF.sub.3 463 H
(s)CH.sub.3 H H H CH N CF.sub.3 464 CH.sub.3 (s)CH.sub.3 H H H CH N
CF.sub.3 465 CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CF.sub.3 466
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H H CH N CF.sub.3 467
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H H CH N CF.sub.3 468
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H H CH N CF.sub.3 469
CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH N CF.sub.3 470
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H H CH N CF.sub.3 471
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H H CH N CF.sub.3 472
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H H CH N CF.sub.3 473
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H H CH N CF.sub.3 474
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H H CH N CF.sub.3 475 H H H
H CH.sub.3 CH CH CH(CH.sub.3).sub.2 476 CH.sub.3 H H H CH.sub.3 CH
CH CH(CH.sub.3).sub.2 477 CH.sub.2CH.sub.3 H H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 478 CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 479 CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH
CH CH(CH.sub.3).sub.2 480 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3
CH CH CH(CH.sub.3).sub.2 481 H (s)CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 482 CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 483 CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH
CH CH(CH.sub.3).sub.2 484 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H
CH.sub.3 CH CH CH(CH.sub.3).sub.2 485 CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H CH.sub.3 CH CH CH(CH.sub.3).sub.2 486
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 487 CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 488 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
CH.sub.3 CH CH CH(CH.sub.3).sub.2 489 CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H CH.sub.3 CH CH CH(CH.sub.3).sub.2 490
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 491 CH.sub.3 (R)CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 492 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 CH CH CH(CH.sub.3).sub.2 493 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H CH.sub.3 CH CH CH(CH.sub.3).sub.2 494
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 495 CH.sub.3 H CH.sub.3 H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 496 CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H
CH.sub.3 CH CH CH(CH.sub.3).sub.2 497 CH.sub.2-c-C.sub.3H.sub.5 H
CH.sub.3 H CH.sub.3 CH CH CH(CH.sub.3).sub.2 498
CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 499 CH.sub.3 CH.sub.3 H CH.sub.3 CH.sub.3 CH CH
CH(CH.sub.3).sub.2 500 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3
CH.sub.3 CH CH CH(CH.sub.3).sub.2 501 CH.sub.2-c-C.sub.3H.sub.5
CH.sub.3 H CH.sub.3 CH.sub.3 CH CH CH(CH.sub.3).sub.2 502
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3 CH.sub.3 CH CH
CH(CH.sub.3).sub.2 503 CH.sub.3 CH.sub.3 CH.sub.3 H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 504 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H
CH.sub.3 CH CH CH(CH.sub.3).sub.2 505 CH.sub.2-c-C.sub.3H.sub.5
CH.sub.3 CH.sub.3 H CH.sub.3 CH CH CH(CH.sub.3).sub.2 506
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 507 (S)(CH.sub.2).sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 508 (S)(CH.sub.2).sub.4 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 509 rac(CH.sub.2).sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 510 rac(CH.sub.2).sub.4 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 511 (R)(CH.sub.2).sub.3 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 512 (R)(CH.sub.2).sub.4 H H CH.sub.3 CH CH
CH(CH.sub.3).sub.2 513 CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 C--Cl
CH CH(CH.sub.3).sub.2 514 CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3
C--Cl CH CH(CH.sub.3).sub.2 515 CH.sub.2CH.sub.2CH.sub.3 H H H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 516 CH.sub.2CH.dbd.CH.sub.2
(s)CH.sub.3 H H CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 517
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 518 CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3
C--Cl CH CH(CH.sub.3).sub.2 519 CH.sub.2CH.sub.2CH.sub.3
(s)CH.sub.3 H H CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 520
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 521 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 522 CH.sub.2CH.sub.3
rac-CH.sub.3 H H CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 523
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 524 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 525 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 526
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 527 CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3
C--Cl CH CH(CH.sub.3).sub.2 528 CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3
H CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 529
CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 530 CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 531 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 H CH.sub.3 CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 532
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 533 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 534 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 CH.sub.3 H CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 535
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H CH.sub.3 C--Cl CH
CH(CH.sub.3).sub.2 536 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 537 (CH.sub.2).sub.3 H H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 538 (CH.sub.2).sub.4 H H
CH.sub.3 C--Cl CH CH(CH.sub.3).sub.2 539 CH.sub.2CH.dbd.CH.sub.2 H
H H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 540
CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 541 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 CH
C--Cl CH(CH.sub.3).sub.2 542 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H
H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 543
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 544 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 545 CH.sub.2CH.sub.3
(s)CH.sub.3 H H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 546
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 547 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 548 CH.sub.2CH.sub.3
rac-CH.sub.3 H H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 549
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 550 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 551 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 552
CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 553 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 554 CH.sub.2CH.dbd.CH.sub.2 H
CH.sub.3 H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 555
CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 556 CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 557 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 H CH.sub.3 CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 558
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 559 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 560 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 CH.sub.3 H CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 561
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H CH.sub.3 CH C--Cl
CH(CH.sub.3).sub.2 562 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 563 (CH.sub.2).sub.3 H H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 564 (CH.sub.2).sub.4 H H
CH.sub.3 CH C--Cl CH(CH.sub.3).sub.2 565 CH.sub.2CH.dbd.CH.sub.2 H
H H CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 566
CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 567 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3
C--CH.sub.3 CH CH(CH.sub.3).sub.2 568 CH.sub.2CH.dbd.CH.sub.2
(s)CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 569
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 570 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 571
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 572 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 573
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 574 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 575
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 576 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 577
CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 578 CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H
CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 579
CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H CH.sub.3 C--CH.sub.3 CH
CH(CH.sub.3).sub.2 580 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3
CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 581
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3 CH.sub.3 C--CH.sub.3
CH CH(CH.sub.3).sub.2
582 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3 CH.sub.3
C--CH.sub.3 CH CH(CH.sub.3).sub.2 583 CH.sub.2CH.dbd.CH.sub.2
CH.sub.3 CH.sub.3 H CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 584
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H CH.sub.3 C--CH.sub.3
CH CH(CH.sub.3).sub.2 585 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3
CH.sub.3 H CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 586
(CH.sub.2).sub.3 H H CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 587
(CH.sub.2).sub.4 H H CH.sub.3 C--CH.sub.3 CH CH(CH.sub.3).sub.2 588
CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 589 CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH
C--CH.sub.3 CH(CH.sub.3).sub.2 590 CH.sub.2CH.sub.2CH.sub.3 H H H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 591
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 592 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 593
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 594 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 595
CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 596 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 597
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 598 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 599
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 600 CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 601
CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 602 CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H
CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 603
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3 CH.sub.3 CH C--CH.sub.3
CH(CH.sub.3).sub.2 604 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H
CH.sub.3 CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 605
CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 H CH.sub.3 CH.sub.3 CH
C--CH.sub.3 CH(CH.sub.3).sub.2 606 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3
CH.sub.3 H CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 607
CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H CH.sub.3 CH
C--CH.sub.3 CH(CH.sub.3).sub.2 608 CH.sub.2CH.sub.2CH.sub.3
CH.sub.3 CH.sub.3 H CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 609
(CH.sub.2).sub.3 H H CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 610
(CH.sub.2).sub.4 H H CH.sub.3 CH C--CH.sub.3 CH(CH.sub.3).sub.2 611
H H H H CH.sub.3 CH CH c-C.sub.3H.sub.5 612 CH.sub.3 H H H CH.sub.3
CH CH c-C.sub.3H.sub.5 613 CH.sub.2CH.sub.3 H H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 614 CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 615 CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 616 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 617 H (s)CH.sub.3 H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 618 CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 619 CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH
CH c-C.sub.3H.sub.5 620 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H
CH.sub.3 CH CH c-C.sub.3H.sub.5 621 CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 622
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 623 CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 624 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
CH.sub.3 CH CH c-C.sub.3H.sub.5 625 CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 626
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 627 CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 CH
CH c-C.sub.3H.sub.5 628 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 CH CH c-C.sub.3H.sub.5 629 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 630
CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 CH CH
c-C.sub.3H.sub.5 631 CH.sub.3 H CH.sub.3 H CH.sub.3 CH CH
c-C.sub.3H.sub.5 632 CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H CH.sub.3
CH CH c-C.sub.3H.sub.5 633 CH.sub.2-c-C.sub.3H.sub.5 H CH.sub.3 H
CH.sub.3 CH CH c-C.sub.3H.sub.5 634 CH.sub.2CH.sub.2CH.sub.3 H
CH.sub.3 H CH.sub.3 CH CH c-C.sub.3H.sub.5 635 CH.sub.3 CH.sub.3 H
CH.sub.3 CH.sub.3 CH CH c-C.sub.3H.sub.5 636
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3 CH.sub.3 CH CH
c-C.sub.3H.sub.5 637 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 H CH.sub.3
CH.sub.3 CH CH c-C.sub.3H.sub.5 638 CH.sub.2CH.sub.2CH.sub.3
CH.sub.3 H CH.sub.3 CH.sub.3 CH CH c-C.sub.3H.sub.5 639 CH.sub.3
CH.sub.3 CH.sub.3 H CH.sub.3 CH CH c-C.sub.3H.sub.5 640
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H CH.sub.3 CH CH
c-C.sub.3H.sub.5 641 CH.sub.2-c-C.sub.3H.sub.5 CH.sub.3 CH.sub.3 H
CH.sub.3 CH CH c-C.sub.3H.sub.5 642 CH.sub.2CH.sub.2CH.sub.3
CH.sub.3 CH.sub.3 H CH.sub.3 CH CH c-C.sub.3H.sub.5 643
(s)(CH.sub.2).sub.3 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 644
(s)(CH.sub.2).sub.4 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 645
rac(CH.sub.2).sub.3 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 646
rac(CH.sub.2).sub.4 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 647
(R)(CH.sub.2).sub.3 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 648
(R)(CH.sub.2).sub.4 H H CH.sub.3 CH CH c-C.sub.3H.sub.5 649
CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 CH C--Cl c-C.sub.3H.sub.5
650 CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH C--Cl
c-C.sub.3H.sub.5 651 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 CH
C--Cl c-C.sub.3H.sub.5 652 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H
CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 653 CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 654
CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH C--Cl c-C.sub.3H.sub.5
655 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH C--Cl
c-C.sub.3H.sub.5 656 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 657 CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 658
CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH C--Cl
c-C.sub.3H.sub.5 659 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H
CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 660 CH.sub.2CH.dbd.CH.sub.2
(R)CH.sub.3 H H CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 661
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H CH.sub.3 CH C--Cl
c-C.sub.3H.sub.5 662 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H
CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 663 CH.sub.2CH.sub.3 (R)CH.sub.3
H H CH.sub.3 CH C--Cl c-C.sub.3H.sub.5 664 CH.sub.2CH.dbd.CH.sub.2
H H H CH.sub.3 CH C--CH.sub.3 c-C.sub.3H.sub.5 665
CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH C--CH.sub.3
c-C.sub.3H.sub.5 666 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 CH
C--CH.sub.3 c-C.sub.3H.sub.5 667 CH.sub.2CH.dbd.CH.sub.2
(s)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3 c-C.sub.3H.sub.5 668
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
c-C.sub.3H.sub.5 669 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 c-C.sub.3H.sub.5 670
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
c-C.sub.3H.sub.5 671 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 c-C.sub.3H.sub.5 672
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
c-C.sub.3H.sub.5 673 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 c-C.sub.3H.sub.5 674
CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H CH.sub.3 CH C--CH.sub.3
c-C.sub.3H.sub.5 675 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H
CH.sub.3 CH C--CH.sub.3 c-C.sub.3H.sub.5 676
CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 C--Cl CH c-C.sub.3H.sub.5
677 CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 C--Cl CH
c-C.sub.3H.sub.5 678 CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 C--Cl
CH c-C.sub.3H.sub.5 679 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H
CH.sub.3 C--Cl CH c-C.sub.3H.sub.5 680 CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H CH.sub.3 C--Cl CH c-C.sub.3H.sub.5 681
CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 C--Cl CH c-C.sub.3H.sub.5
682 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 C--Cl CH
c-C.sub.3H.sub.5 683 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
CH.sub.3 C--Cl CH c-C.sub.3H.sub.5 684 CH.sub.2-c-C.sub.3H.sub.5
rac-CH.sub.3 H H CH.sub.3 C--Cl CH c-C.sub.3H.sub.5 685
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 C--Cl CH
c-C.sub.3H.sub.5 686 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 C--Cl CH c-C.sub.3H.sub.5 687 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H CH.sub.3 C--Cl CH c-C.sub.3H.sub.5 688
CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 C--Cl CH c-C.sub.3H.sub.5
689 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H CH.sub.3 C--Cl CH
c-C.sub.3H.sub.5 690 CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3
C--CH.sub.3 CH c-C.sub.3H.sub.5 691 CH.sub.2-c-C.sub.3H.sub.5 H H H
CH.sub.3 C--CH.sub.3 CH c-C.sub.3H.sub.5 692
CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 C--CH.sub.3 CH
c-C.sub.3H.sub.5 693 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH c-C.sub.3H.sub.5 694
CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
c-C.sub.3H.sub.5 695 CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH c-C.sub.3H.sub.5 696
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
c-C.sub.3H.sub.5 697 CH.sub.2-c-C.sub.3H.sub.5 rac-CH.sub.3 H H
CH.sub.3 C--CH.sub.3 CH c-C.sub.3H.sub.5 698
CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H CH.sub.3 C--CH.sub.3 CH
c-C.sub.3H.sub.5 699 CH.sub.3 H H H CH.sub.3 CH CH C.sub.2H.sub.5
700 CH.sub.2CH.dbd.CH.sub.2 H H H CH.sub.3 CH CH C.sub.2H.sub.5 701
CH.sub.2-c-C.sub.3H.sub.5 H H H CH.sub.3 CH CH C.sub.2H.sub.5 702
CH.sub.2CH.sub.2CH.sub.3 H H H CH.sub.3 CH CH C.sub.2H.sub.5 703
CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH C.sub.2H.sub.5 704
CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H CH.sub.3 CH CH
C.sub.2H.sub.5 705 CH.sub.2-c-C.sub.3H.sub.5 (s)CH.sub.3 H H
CH.sub.3 CH CH C.sub.2H.sub.5 706 CH.sub.2CH.sub.3 (s)CH.sub.3 H H
CH.sub.3 CH CH C.sub.2H.sub.5 707 CH.sub.2CH.sub.2CH.sub.3
(s)CH.sub.3 H H CH.sub.3 CH CH C.sub.2H.sub.5 708
CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H CH.sub.3 CH CH
C.sub.2H.sub.5 709 CH.sub.2CH.sub.2CH.sub.3 rac-CH.sub.3 H H
CH.sub.3 CH CH C.sub.2H.sub.5 710 CH.sub.3 (R)CH.sub.3 H H CH.sub.3
CH CH C.sub.2H.sub.5 711 CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H
CH.sub.3 CH CH C.sub.2H.sub.5 712 CH.sub.2-c-C.sub.3H.sub.5
(R)CH.sub.3 H H CH.sub.3 CH CH C.sub.2H.sub.5 713
CH.sub.2CH.dbd.CH.sub.2 H CH.sub.3 H CH.sub.3 CH CH C.sub.2H.sub.5
714 CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H CH.sub.3 CH CH
C.sub.2H.sub.5 715 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3
CH.sub.3 CH CH C.sub.2H.sub.5 716 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3
H CH.sub.3 CH.sub.3 CH CH C.sub.2H.sub.5 717
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H CH.sub.3 CH CH
C.sub.2H.sub.5 718 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
CH.sub.3 CH CH C.sub.2H.sub.5 719 (s)(CH.sub.2).sub.3 H H CH.sub.3
CH CH C.sub.2H.sub.5 720 (s)(CH.sub.2).sub.4 H H CH.sub.3 CH CH
C.sub.2H.sub.5 721 rac(CH.sub.2).sub.3 H H CH.sub.3 CH CH
C.sub.2H.sub.5 722 rac(CH.sub.2).sub.4 H H CH.sub.3 CH CH
C.sub.2H.sub.5 723 H H H H CH.sub.3 CH CH CH.dbd.CH.sub.2 724
CH.sub.3 H H H CH.sub.3 CH CH CH.dbd.CH.sub.2 725 CH.sub.2CH.sub.3
H H H CH.sub.3 CH CH CH.dbd.CH.sub.2 726 CH.sub.2CH.dbd.CH.sub.2 H
H H CH.sub.3 CH CH CH.dbd.CH.sub.2 727 CH.sub.2-c-C.sub.3H.sub.5 H
H H CH.sub.3 CH CH CH.dbd.CH.sub.2 728 CH.sub.2CH.sub.2CH.sub.3 H H
H CH.sub.3 CH CH CH.dbd.CH.sub.2 729 H (s)CH.sub.3 H H CH.sub.3 CH
CH CH.dbd.CH.sub.2 730 CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
CH.dbd.CH.sub.2 731 CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
CH.dbd.CH.sub.2 732 CH.sub.2CH.dbd.CH.sub.2 (s)CH.sub.3 H H
CH.sub.3 CH CH CH.dbd.CH.sub.2 733 CH.sub.2-c-C.sub.3H.sub.5
(s)CH.sub.3 H H CH.sub.3 CH CH CH.dbd.CH.sub.2 734
CH.sub.2CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH
CH.dbd.CH.sub.2 735 CH.sub.2CH.dbd.CH.sub.2 rac-CH.sub.3 H H
CH.sub.3 CH CH CH.dbd.CH.sub.2 736 CH.sub.2CH.sub.2CH.sub.3
rac-CH.sub.3 H H CH.sub.3 CH CH CH.dbd.CH.sub.2 737
CH.sub.2CH.sub.3 (s)CH.sub.3 H H CH.sub.3 CH CH CH.dbd.CH.sub.2 738
CH.sub.2CH.dbd.CH.sub.2 (R)CH.sub.3 H H CH.sub.3 CH CH
CH.dbd.CH.sub.2
739 CH.sub.2-c-C.sub.3H.sub.5 (R)CH.sub.3 H H CH.sub.3 CH CH
CH.dbd.CH.sub.2 740 CH.sub.2CH.sub.2CH.sub.3 (R)CH.sub.3 H H
CH.sub.3 CH CH CH.dbd.CH.sub.2 741 CH.sub.2CH.dbd.CH.sub.2 H
CH.sub.3 H CH.sub.3 CH CH CH.dbd.CH.sub.2 742
CH.sub.2CH.sub.2CH.sub.3 H CH.sub.3 H CH.sub.3 CH CH
CH.dbd.CH.sub.2 743 CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 H CH.sub.3
CH.sub.3 CH CH CH.dbd.CH.sub.2 744 CH.sub.2CH.sub.2CH.sub.3
CH.sub.3 H CH.sub.3 CH.sub.3 CH CH CH.dbd.CH.sub.2 745
CH.sub.2CH.dbd.CH.sub.2 CH.sub.3 CH.sub.3 H CH.sub.3 CH CH
CH.dbd.CH.sub.2 746 CH.sub.2CH.sub.2CH.sub.3 CH.sub.3 CH.sub.3 H
CH.sub.3 CH CH CH.dbd.CH.sub.2 747 (CH.sub.2).sub.3 H H CH.sub.3 CH
CH CH.dbd.CH.sub.2 748 (CH.sub.2).sub.4 H H CH.sub.3 CH CH
CH.dbd.CH.sub.2 rac: racemate; (S): S configuration; (R) R
configuration.
[0065] Other examples of compounds according to the invention are
the compounds of the general formulae Ia.3, Ib, Ic, Id, Ie and If:
##STR10## in which R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3,
X, Y and R.sup.b have the meanings specified in one line in Table
1.
[0066] Among the compounds of the general formula I, preference is
also given to the compounds of the general formula Ig ##STR11## in
which n, k, R.sup.1, R.sup.2, R.sup.a, R.sup.b, A.sup.1, A.sup.2,
A.sup.3, X and Y have the meanings given for formula Ia.
[0067] Among the compounds of the general formula I, preference is
also given to the compounds of the general formula Ih ##STR12## in
which n, k, R.sup.1, R.sup.2, R.sup.a, R.sup.b, A.sup.1, A.sup.2,
A.sup.3, X and Y have the meanings given for formula Ia.
[0068] Among the compounds of general formulae Ig and Ih,
preference is given to the compounds of general formula Ig.1, Ig.2,
Ih.1 and Ih.2 ##STR13## in which n, q, q', X, Y, R.sup.1, R.sup.2,
R.sup.a and R.sup.b have the meanings mentioned previously for
formulae Ia.1 and Ia.2 and R is CH.sub.2 (compounds 1g.1 and Ig.2)
or O (compounds Ih.1 or Ih.2).
[0069] Examples of compounds of the formula Ig.1 and Ih.1 are the
compounds of the following general formulae Ig.1a, Ig.1b, Ig.1c,
Ig.1d, Ig.1e, Ig.1f, Ig.1g, Ig.1h,.Ig.1k, Ih.1a, Ih.1b, Ih.1c,
Ih.1h, Ih.1e, Ih.1f, Ih.1g, Ih.1h and Ih.1k: ##STR14## ##STR15## in
which R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, X, Y and R.sup.b have
the meanings specified in one of the lines 1 to 474 in Table 1.
[0070] Examples of compounds of the formula Ig.1 and Ih.1 are the
compounds of the following general formulae Ig.2a, Ig.2b, Ig.2c,
Ig.2d, Ig.2e, Ih.2a, Ih.2b, Ih.2c, Ih.2d and Ih.2e: ##STR16## in
which R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, X, Y and R.sup.b have
the meanings specified in one of the lines 1 to 474 in Table 1.
[0071] The compounds I according to the invention are prepared in
analogy with methods known from the literature. An important
approach to the compounds according to the invention with R being O
or N--R.sup.3 is offered by the reaction of a hetarylcompound If
with an arylsulfonic acid derivative III as depicted in scheme 1.
##STR17##
[0072] In scheme 1, n, R.sup.1, R.sup.2, R.sup.3, Ar and Q have the
previously mentioned meanings. R is O or N--R.sup.3. X is a
nucleophilically displaceable leaving group, in particular a
halogen atom and, especially, chlorine or bromine. The reaction
depicted in scheme 1 takes place under the reaction conditions
which are customary for preparing arylsulfonamide compounds or
arylsulfonic esters, respectively, and which are described, for
example, in J. March, Advanced Organic Chemistry, 3rd edition, John
Wiley & Sons, New York, 1985 p 444 and the literature cited
therein, European J. Org. Chem. 2002 (13), pp. 2094-2108,
Tetrahedron 2001, 57 (27) pp. 5885-5895, Bioorganic and Medicinal
Chemistry Letters, 2000, 10(8), pp. 835-838 and Synthesis 2000 (1),
pp. 103-108.
[0073] The reaction customarily takes place in an inert solvent,
for example in an ether, such as diethyl ether, diisopropyl ether,
methyl tert-butyl ether or tetrahydrofuran, a halohydrocarbon, such
as dichloromethane, an aliphatic or cycloaliphatic hydrocarbon,
such as pentane, hexane or cyclohexane, or an aromatic hydrocarbon,
such as toluene, xylene, cumene and the like, or in a mixture of
the abovementioned solvents.
[0074] The reaction of II with III is customarily carried out in
the presence of an auxiliary base. Suitable bases are inorganic
bases, such as sodiumcarbonate or potassiumcarbonate, or
sodiumhydrogencarbonate or potassiumhydrogencarbonate, and organic
bases, for example trialkylamines, such as triethylamine, or
pyridine compounds, such as pyridine, lutidine and the like. The
latter compounds can at the same time serve as solvents. The
auxiliary base is customarily employed in at least equimolar
quantities, based on the amine compound II.
[0075] The compounds of the general formula II are known per se or,
in case R is N--R.sup.3a, can be prepared in the manner shown in
schemes 2. ##STR18##
[0076] In scheme 2, n, R.sup.2 and Q have the previously mentioned
meanings. R.sup.1' has the meanings different from hydrogen which
are specified for R.sup.1 or is a suitable protecting group.
Suitable protecting groups are disclosed, for example, in P.
Kocienski, Protecting Groups, Thieme-Verlag, Stuttgart 2000,
Chapter 6. Y is a nucleophilically displaceable leaving group, in
particular a halogen atom, e.g. chlorine or bromine, or an
alkylsulfonyl group, e.g. methylsulfonyl.
[0077] The reaction depicted in step a) in scheme 2 takes place
under the reaction conditions which are customary for a
nucleophilic substitution on an aromatic radical and which are
described, for example, in Tetrahedron 1999, 55(33), pp.
10243-10252, J. Med. Chem. 1997, 40(22), pp. 3679-3686 and
Synthetic Communications, 1993, 23(5), pp. 591-599. Where
appropriate, it can be advantageous to convert a ring nitrogen atom
in the Q group into its N-oxide (see, for example, Angew. Chem.
Int. Ed. Engl.,2002 41(1 1), pp. 1937-1940, J. Med. Chem. 1985,
28(2), pp. 248-252 and Tetrahedron Lett. 2002 43(17) pp.
3121-3123). This approach has proved to be of value, in particular,
for preparing compounds I in which Q is a pyridin-2,4-diyl group.
In connection with the subsequent reduction of the nitro group in
VI (step b), the N-oxide group is also reduced. For this, the
reduction is carried out, for example, in the presence of indium
salts.
[0078] If 5-bromonitropyridine is used as compound V in step a) in
accordance with scheme 2, the coupling is also achieved under
palladium catalysis in the presence of an auxiliary base, for
example an alkali metal carbonate such as cesium carbonate.
Particularly suitable palladium catalysts in this connection are
palladium(0) compounds or palladium compounds which are able to
form a palladium(0) compound under reaction conditions, e.g.
palladium dichloride, tetrakis(triphenylphosphine)palladium(0),
tris(dibenzylideneacetone)dipalladium(0), advantageously in
combination with phosphine ligands, e.g. triarylphosphines, such as
triphenylphosphine, trialkylphosphines, such as tributylphosphine,
and cycloalkylphosphines, such as tricyclohexylphosphine, and,
especially, using phosphine chelate ligands, such as
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl. The conditions which
are required for reactions of this nature are described, for
example, in Tetrahedron Lett. 2001, 42(22), p. 3681 and Tetrahedron
Lett. 2002, 43(12), pp. 2171-2173.
[0079] In step b), the nitro group in VI is reduced to the NH.sub.2
group in II. Subsequently, in step c), the NH.sub.2 group can be
converted into a --NR.sup.3'H group, in which R.sup.3' has the
meanings different from hydrogen which are specified for
R.sup.3.
[0080] The reaction conditions which are required for step b)
correspond to the customary conditions for reducing aromatic nitro
groups which have been described extensively in the literature
(see, for example, J. March, Advanced Organic Chemistry, 3rd ed.,
J. Wiley & Sons, New-York, 1985, p.1183 and the literature
cited in this reference).
[0081] The reduction is achieved, for example, by reacting the
nitro compound VII with a metal such as iron, zinc or tin under
acidic reaction conditions, i.e. using nascent hydrogen, or using a
complex hydride such as lithium aluminum hydride or sodium
borohydride, preferably in the presence of transition metal
compounds of nickel or cobalt such as
NiCl.sub.2(P(phenyl).sub.3).sub.2, or COCl.sub.2,(see Ono et al.
Chem. Ind. (London), 1983 p.480), or using NaBH.sub.2S.sub.3 (see
Lalancette et al. Can. J. Chem. 49, 1971, p. 2990), with it being
possible to carry out these reductions, depending on the given
reagent, in substance or in a solvent or diluent. Alternatively,
the reduction of VI to II can be carried out with hydrogen in the
presence of a transition metal catalyst, e.g. using hydrogen in the
presence of catalysts based on platinum, palladium, nickel,
ruthenium or rhodium. The catalysts can contain the transition
metal in elemental form or in the form of a complex compound, of a
salt or of an oxide of the transition metal, with it being
possible, for the purpose of modifying the activity, to use
customary coligands, e.g. organic phosphine compounds, such as
triphenylphosphine, tricyclohexylphosphine or tri-n-butylphosphines
or phosphites. The catalyst is customarily employed in quantities
of from 0.001 to 1 mol per mol of compound VI, calculated as
catalyst metal. In a preferred variant, the reduction is effected
using tin(II) chloride in analogy with the methods described in
Bioorganic and, Medicinal Chemistry Letters, 2002, 12(15), pp.
1917-1919 and J. Med. Chem. 2002, 45(21), pp. 4679-4688. The
reaction of VI with tin(II) chloride is preferably carried out in
an inert organic solvent, preferably an alcohol such as methanol,
ethanol, isopropanol or butanol.
[0082] Reducing VI results in compounds II in which R.sup.3 is
hydrogen. Customary methods can then be used to react these
compounds with an alkylating agent R.sup.3-X, in which R.sup.3' is
C.sub.1--C-.sub.4-alkyl and X is a nucleophilically displaceable
leaving group (e.g. halogen, such as chlorine, bromine or iodine),
resulting in a compound II in which R.sup.3=alkyl (step c). The
reaction conditions which are required for this are disclosed, for
example, in WO 02/83652, Tetrahedron 2000, 56(38) pp. 7553-7560 and
Synlett. 2000 (4), pp. 475-480.
[0083] The compound I can also be prepared by the route depicted in
scheme 3: ##STR19##
[0084] In scheme 3, n, R, R.sup.1, R.sup.2, Ar and 0 have the
previously mentioned meanings. Y is a nucleophilically displaceable
leaving group, in particular a halogen atom, e.g. chlorine or
bromine, or an alkylsulfonyl group, e.g. methylsulfonyl. The
reaction of VlI with VIII, as depicted in scheme 3, takes place
under the reaction conditions specified for scheme 2, step a).
Compounds of the general formulae VII and VIII are known or can be
prepared in analogy with the methods known from the literature.
Compounds or the formula V, wherein R is N--R.sup.3 or an oxygen
atom can be prepared by amidation of the the corresponding
aminocompound X-Q-NHR.sup.3 (or esterification of the corresponding
hydroxycompound X-Q-OH) with a sulfonylhalide, especially with a
sulfonylchloride of the formula Z--SO.sub.2--Ar, wherein Z is
halogen, especially chlorine or bromine, according to standard
methods of organic chemistry (see e.g. J. March, Advanced Organic
Chemistry, 3.sup.rd edition, John Wiley & Sons, New York, 1985
p 444 and the literature cited therein).
[0085] Compounds of general formula I, in which R.sup.1 is an allyl
group, can be converted into compounds possessing different R.sup.1
substituents using the synthetic route shown in scheme 4.
##STR20##
[0086] In scheme 4, n, R, R.sup.2, Ar and Q have the previously
mentioned meanings. The elimination of the allyl group, as depicted
in step a) in scheme 4, is achieved, for example, by reacting I
[R.sup.1=allyl] with an allyl trapping agent, such as
mercaptobenzoic acid or 1,3-dimethylbarbituric acid, in the
presence of catalytic quantities of palladium (0) compounds or
palladium compounds which are able to form a palladium(0) compound
under reaction conditions, e.g. palladium dichloride,
tetral(is(triphenylphosphine)palladium(0) or
tris(dibenzylideneacetone)dipalladium(0), advantageously in
combination with phosphine ligands, e.g. triarylphosphines, such as
triphenylphosphine, trialkylphosphines, such as tributylphosphine,
and cycloalkylphosphines, such as tricyclohexylphosphine, and
especially with phosphine chelate ligands, such as
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl or
1,4-bis(diphenylphosphino)butane, using methods known from the
literature (with regard to eliminating N-allyl in the presence of
mercaptobenzoic acid, see WO 94/24088; with regard to eliminating
in the presence of 1,3-dimethylbarbituric acid, see J. Am. Chem.
Soc. 2001, 123 (28), pp. 6801-6808 and J. Org. Chem 2002, 67(11)
pp. 3718-3723). Alternatively, the elimination of N-allyl, as
depicted in scheme 4 step a), can also be effected by reacting in
the presence of rhodium compounds, such as
tris(triphenylphosphine)chlororhodium(1), using methods known from
the literature (see J. Chem. Soc., Perkin Transaction I: Organic
and BioOrganic Chemistry 1999 (21) pp. 3089-3104 and Tetrahedron
Asymmetry 1997, 8(20), pp. 3387-3391).
[0087] The resulting piperazine compound I [R.sup.1=H] can then be
reacted, in a known manner, in the sense of an alkylation, with a
compound R.sup.1-X. In this compound, R.sup.1 is
C.sub.1--C.sub.4-alkyl, C.sub.3--C.sub.6-Cycloalkyl,
C.sub.1--C.sub.4-haloalkyl,
C.sub.1--C.sub.4-alkoxy-C.sub.1--C.sub.4-alkyl or
C.sub.3--C.sub.6-cycloalkyl-C.sub.1--C.sub.4-alkyl and X is a
nucleophilically displaceable leaving group, e.g. halogen,
trifluoroacetate, alkylsulfonate, arylsulfonate, alkyl sulfate and
the like. The reaction conditions which are required for the
alkylation in step b) have been adequately disclosed, e.g. in
Bioorganic and Medicinal Chemistry Lett. 2002, 12(7), pp. 2443-2446
and also 2002, 12(5), pp.1917-1919.
[0088] The conversion, as depicted in scheme 4, step b), of the
piperazine compound I [R.sup.1=H] obtained in step a) can also be
achieved, in the sense of a reductive amination, by reacting I
[R.sup.1=H] with a suitable ketone or aldehyde in the presence of a
reducing agent, e.g. in the presence of a borohydride such as
sodium borohydride, sodium cyanoborohydride or sodium
triacetoxyborohydride. The skilled person is familiar with the
reaction conditions which are required for a reductive amination,
e.g. from Bioorganic and Medicinal Chemistry Left. 2002, 12(5), pp.
795-798 and 12(7) pp. 1269-1273.
[0089] The conversion, as depicted in scheme 4, step b), of the
piperazine compound I [R.sup.1=H] obtained in step a) can also be
achieved by successive acylation and subsequent reduction of the
acylation product, using the method depicted in scheme 4a:
##STR21##
[0090] In scheme 4a, n, R, R.sup.2, Ar and Q have the previously
mentioned meanings. The acylation in step a) and the reduction in
step b) are effected using standard methods of organic chemistry as
are described, for example, in J. March, Advanced Organic
Chemistry, 3rd ed. J. Wiley & Sons, New York 1985, p. 370 and
373 (acylation) and p. 1099 f. and in the literature cited in this
publication (with regard to acylation, see also Synth. Commun.
1986, 16, p. 267, and with regard to reduction, see also J.
Heterocycl. Chem. 1979, 16, p. 1525).
[0091] In compounds of the general formula I which carry a halogen
atom, in particular bromine or iodine, on the aromatic radical Ar,
the halogen atom can be converted into an alkyl, alkenyl,
cycloalkyl, alkynyl or cycloalkylalkyl group using methods which
are known per se. The conversion is achieved by coupling the halo
compound I to an alkyl-, alkenyl-, alkynyl-, cycloalkyl- or
cycloalkylalkyl-boronic acid compound under the conditions of a
Suzuki coupling as is described, for example, in Tetrahedron Lett.
2002, 43, pp. 6987-6990; Chem. Rev. 1995, 95, pp. 2457-2483 and J.
Org. Chem. 66(21) (2001), pp. 7124-7128.
[0092] Compounds of the formula I, wherein R is CR.sup.aR.sup.3b,
can be also prepared by the synthetic route illustrated in scheme
5: ##STR22##
[0093] In scheme 5, n, R.sup.1, R.sup.2, Q, R.sup.3a, R.sup.3b and
Ar are as defined above. L is a nucleophilically displaceable
leaving group, in particular a halogen atom such as chlorine or
bromine or a sulfonate group, e.g. a
C.sub.1--C.sub.4-alkylsulfonate such as methanesulfonate or an
arylsulfonate such benzenesulfoante or tosylate (toluene
sulfonate). L may also be OH, when R.sup.3a, R.sup.3b are different
from hydrogen. The reaction depicted in the first step of scheme 5
takes place under the reaction conditions which are customary for
preparing arylsulfide compounds which are described, for example,
in J. March, Advanced Organic Chemistry, 3.sup.rd edition, John
Wiley & Sons, New York, 1985 p 360 to 362, and in the
literature cited therein.
[0094] In the second step of scheme 5 the sulfide X obtained in the
first step is oxidized to the corresponding sulfone I
(R=CR.sup.3aR.sup.3b) under reaction conditions which are customary
for preparing arylsulfone compounds from the corresponding
arylsulfides and which are described, for example, in J. March,
Advanced Organic Chemistry, .sub.3rd edition, John Wiley &
Sons, New York, 1985 p 1089 f. and in the literature cited
therein.
[0095] The compounds of the formula IX are known in the art or can
be prepared according to the method depicted in scheme 6:
##STR23##
[0096] In scheme 6, n, R.sup.1, R.sup.2, Q, R.sup.3a, R.sup.3b and
Ar are as defined above. Hal is halogen, especially chlorine,
bromine or iodine. In step (a) of scheme 6 the halogen compound XI
is first metallized, i.e. converted into the corresponding lithium
compound or magnesium compound by standard methods of organic
chemistry and the thus obtained metal compound is reacted with an
aldehyde or ketone to obtain the alcohol XII (see e.g. Tetrahedron
2003, 59 (24), 4303-4308). In step (b) he OH group of XIl is then
converted into a suitable leaving group, e.g. into a halogen atom
by reaction with thionylhalide such as SOCl.sub.2 or
phosphorylhalide such as POCl.sub.3, or into an alkylsulfonate or
arylsulfonate by reaction with an alkylsulfonylhalide such as
methanesulfonylchloride or with an arylsulfonylhalide such as
toluoenesulfonylchloride (see e.g. J. Med. Chem. 1985, 28
(12),1790-1796).
[0097] Alternatively the halogen compound XI is converted into the
carbonyl compound XIII (step c, see e.g. J. Med. Chem.1987, 30
(8),1494-1497), which is then reduced (R.sup.3b=H) or reacted with
an alkylgrignard R.sup.3b-Mg-X (X=halogen, e.g. Cl or Br) to obtain
the alcohol XII (step (d), see e.g. J. Org. Chem. 2003, 68 (9),
3736-3738).
[0098] If not otherwise indicated, the above-described reactions
are generally carried out in a solvent at temperatures between room
temperature and the boiling temperature of the solvent employed.
Alternatively, the activation energy which is required for the
reaction can be introduced into the reaction mixture using
microwaves, something which has proved to be of value, in
particular, in the case of the reactions catalyzed by transition
metals (with regard to reactions using microwaves, see Tetrahedron
2001, 57, p. 9199 ff. p. 9225 ff. and also, in a general manner,
"Microwaves in Organic Synthesis", Andre Loupy (Ed.), Wiley-VCH
2002.
[0099] Examples of solvents which can be used are ethers, such as
diethyl ether, diisopropyl ether, methyl tert-butyl ether or
tetrahydrofuran, aprotic polar solvent, such as dimethylformamide,
dimethyl sulfoxide, dimethoxyethane, and acetonitrile, aromatic
hydrocarbons, such as toluene and xylene, ketones, such as acetone
or methyl ethyl ketone, halohydrocarbons, such as dichloromethane,
trichloromethane and dichloroethane, esters, such as ethyl acetate
and methyl butyrate, carboxylic acids, such as acetic acid or
propionic acid, and alcohols, such as methanol, ethanol,
n-propanol, isopropanol and butanol.
[0100] If desired, it is possible for a base to be present in order
to neutralize protons which are released in the reactions. Suitable
bases include inorganic bases, such as sodium carbonate, potassium
carbonate, sodium hydrogen carbonate or potassium hydrogen
carbonate, and, in addition, alkoxides, such as sodium methoxide or
sodium ethoxide, alkali metal hydrides, such as sodium hydride, and
also organometallic compounds, such as butyllithium compounds or
alkylmagnesium compounds, or organic nitrogen bases, such as
triethylamine or pyridine. The latter compounds can at the same
time serve as solvents.
[0101] The crude product is isolated in a customary manner, for
example by filtering, distilling off the solvent or extracting from
the reaction mixture, etc. The resulting compounds can be purified
in a customary manner, for example by means of recrystallizing from
a solvent, by means of chromatography or by means of converting
into an acid addition salt.
[0102] The acid addition salts are prepared in a customary manner
by mixing the free base with a corresponding acid, where
appropriate in solution in an organic solvent, for example a lower
alcohol, such as methanol, ethanol or propanol, an ether, such as
methyl tert-butyl ether or diisopropyl ether, a ketone, such as
acetone or methyl ethyl ketone, or an ester, such as ethyl
acetate.
[0103] The compounds according to the invention of the formula I
are highly selective dopamine D.sub.3 receptor ligands which,
because of their low affinity for other receptors such as D.sub.1
receptors, D.sub.4 receptors, .alpha.1-adrenergic and/or
.alpha.2-adrenergic receptors, muscarinergic receptors, histamine
receptors, opiate receptors and, in particular, dopamine D.sub.2
receptors, give rise to fewer side-effects than do the classic
neuroleptics, which are D.sub.2 receptor antagonists.
[0104] The high affinity of the compounds according to the
invention for D.sub.3 receptors is reflected in very low in-vitro
K.sub.i values of as a rule less than 100 nM (nmoVI), in particular
less than 50 nM and, in particular, of less than 10 nM. The
displacement of [.sup.125I]-iodosulpride can, for example, be used
in receptor binding studies for determining binding affinities for
D.sub.3 receptors.
[0105] The selectivity K.sub.i(D.sub.2)/K.sub.i(D.sub.3) of the
compounds according to the invention is as a rule at least 10,
preferably at least 30, even better at least 50 and particularly
advantageously at least 100. The displacement of [.sup.3H]SCH23390,
[.sup.125I] iodosulpride or [.sup.125I] spiperone can be used, for
example, for carrying out receptor binding studies on D.sub.1,
D.sub.2 and D.sub.4 receptors.
[0106] Because of their binding profile, the compounds can be used
for treating diseases which respond to dopamine D.sub.3 ligands,
i.e. they are effective for treating those disturbances or diseases
in which exerting an influence on (modulating) the dopamine D.sub.3
receptors leads to an improvement in the clinical picture or to the
disease being cured. Examples of these diseases are disturbances or
diseases of the central nervous system.
[0107] Disturbances or diseases of the central nervous system are
understood as meaning disturbances which affect the spinal chord
and, in particular, the brain. Within the meaning of the invention,
the term "disturbance" denotes anomalies which are as a rule
regarded as being pathological conditions or functions and which
can manifest themselves in the form of particular signs, symptoms
and/or malfunctions. While the treatment according to the invention
can be directed toward individual disturbances, i.e. anomalies or
pathological conditions, it is also possible for several anomalies,
which may be causatively linked to each other, to be combined into
patterns, i.e. syndromes, which can be treated in accordance with
the invention.
[0108] The disturbances which can be treated in accordance with the
invention are, in particular, psychiatric and neurological
disturbances. These disturbances include, in particular, organic
disturbances, including symptomatic disturbances, such as psychoses
of the acute exogenous reaction type or attendant psychoses of
organic or exogenous cause, e.g., in association with metabolic
disturbances, infections and endocrinopathogies; endogenous
psychoses, such as schizophrenia and schizotype and delusional
disturbances; affective disturbances, such as depressions, mania
and/or manicdepressive conditions; and also mixed forms of the
above-described disturbances; neurotic and somatoform disturbances
and also disturbances in association with stress; dissociative
disturbances, e.g. loss of consciousness, clouding of
consciousness, double consciousness and personality disturbances;
disturbances in attention and waking/sleeping behavior, such as
behavioral disturbances and emotional disturbances whose onset lies
in childhood and youth, e.g. hyperactivity in children,
intellectual deficits, in particular attention disturbances
(attention deficit disorders), memory disturbances and cognitive
disturbances, e.g. impaired learning and memory (impaired cognitive
function), dementia, narcolepsy and sleep disturbances, e.g.
restless legs syndrome; development disturbances; anxiety states,
delirium; sexlife disturbances, e.g. impotence in men; eating
disturbances, e.g. anorexia or bulimia; addiction; and other
unspecified psychiatric disturbances.
[0109] The disturbances which can be treated in accordance with the
invention also include Parkinson's disease and epilepsy and, in
particular, the affective disturbances connected thereto.
[0110] The addiction diseases include psychic disturbances and
behavioral disturbances which are caused by the abuse of
psychotropic substances, such as pharmaceuticals or narcotics, and
also other addiction diseases, such as addiction to gaming (impulse
control disorders not elsewhere classified). Examples of addictive
substances are: opioids (e.g. morphine, heroin and codeine),
cocaine; nicotine; alcohol; substances which interact with the GABA
chloride channel complex, sedatives, hypnotics and tranquilizers,
for example benzodiazepines; LSD; cannabinoids; psychomotor
stimulants, such as 3,4-methylenedioxy-N-methylamphetamine
(ecstasy); amphetamine and amphetamine-like substances such as
methylphenidate and other stimulants including caffeine. Addictive
substances which come particularly into consideration are opioids,
cocaine, amphetamine or amphetamine-like substances, nicotine and
alcohol.
[0111] With regard to the treatment of addiction diseases,
particular preference is given to those compounds according to the
invention of the formula I which themselves do not possess any
psychotropic effect. This can also be observed in a test using
rats, which, after having been administered compounds which can be
used in accordance with the invention, reduce their self
administration of psychotropic substances, for example cocaine.
[0112] According to another aspect of the present invention, the
compounds according to the invention are suitable for treating
disturbances whose causes can at least partially be attributed to
an anomalous activity of dopamine D.sub.3 receptors.
[0113] According to another aspect of the present invention, the
treatment is directed, in particular, toward those disturbances
which can be influenced, within the sense of an expedient medicinal
treatment, by the binding of preferably exogeneously administered
binding partners (ligands) to dopamine D.sub.3 receptors.
[0114] The diseases which can be treated with the compounds
according to the invention are frequently characterized by
progressive development, i.e. the above-described conditions change
over the course of time; as a rule, the severity increases and
conditions may possibly merge into each other or other conditions
may appear in addition to those which already exist.
[0115] The compounds according to the invention can be used to
treat a large number of signs, symptoms and/or malfunctions which
are connected with the disturbances of the central nervous system
and, in particular, the abovementioned conditions. These signs,
symptoms and/or malfunctions include, for example, a disturbed
relationship to reality, lack of insight and ability to meet
customary social norms or the demands made by life, changes in
temperament, changes in individual drives, such as hunger, sleep,
thirst, etc., and in mood, disturbances in the ability to observe
and combine, changes in personality, in particular emotional
lability, hallucinations, ego-disturbances, distractedness,
ambivalence, autism, depersonalization and false perceptions,
delusional ideas, chanting speech, lack of synkinesia, short-step
gait, flexed posture of trunk and limbs, tremor, poverty of facial
expression, monotonous speech, depressions, apathy, impeded
spontaneity and decisiveness, impoverished association ability,
anxiety, nervous agitation, stammering, social phobia, panic
disturbances, withdrawal symptoms in association with dependency,
maniform syndromes, states of excitation and confusion, dysphoria,
dyskinetic syndromes and tic disturbances, e.g. Huntington's chorea
and Gilles-de-la-Tourette's syndrome, vertigo syndromes, e.g.
peripheral positional, rotational and oscillatory vertigo,
melancholia, hysteria, hypochondria and the like.
[0116] Within the meaning of the invention, a treatment also
includes a preventive treatment (prophylaxis), in particular as
relapse prophylaxis or phase prophylaxis, as well as the treatment
of acute or chronic signs, symptoms and/or malfunctions. The
treatment can be orientated symptomatically, for example as the
suppression of symptoms. It can be effected over a short period, be
orientated over the medium term or can be a long-term treatment,
for example within the context of a maintenance therapy.
[0117] The compounds according to the invention are preferentially
suitable for treating diseases of the central nervous system, in
particular for treating affective disturbances; neurotic
disturbances, stress disturbances and somatoform disturbances and
psychoses, and, in particular, for treating schizophrenia and
depression. Because of their high selectivity with regard to the
D.sub.3 receptor, the compounds I according to the invention are
also suitable for treating disturbances of kidney function, in
particular disturbances of kidney function which are caused by
diabetes mellitus (see WO 00/67847) and, especially, diabetic
nephropathy.
[0118] Within the context of the treatment, the use according to
the invention of the described compounds involves a method. In this
method, an effective quantity of one or more compounds, as a rule
formulated in accordance with pharmaceutical and veterinary
practice, is administered to the individual to be treated,
preferably a mammal, in particular a human being, productive animal
or domestic animal. Whether such a treatment is indicated, and in
which form it is to take place, depends on the individual case and
is subject to medical assessment (diagnosis) which takes into
consideration signs, symptoms and/or malfunctions which are
present, the risks of developing particular signs, symptoms and/or
malfunctions, and other factors.
[0119] As a rule, the treatment is effected by means of single or
repeated daily administration, where appropriate together, or
alternating, with other active compounds or active
compound-containing preparations such that a daily dose of
preferably from about 0.1 to 1000 mg/kg of bodyweight, in the case
of oral administration, or of from about 0.1 to 100 mg/kg of
bodyweight, in the case of parenteral administration, is supplied
to an individual to be treated.
[0120] The invention also relates to the production of
pharmaceutical compositions for treating an individual, preferably
a mammal, in particular a human being, productive animal or
domestic animal. Thus, the ligands are customarily administered in
the form of pharmaceutical compositions which comprise a
pharmaceutically acceptable excipient together with at least one
ligand according to the invention and, where appropriate, other
active compounds. These compositions can, for example, be
administered orally, rectally, transdermally, subcutaneously,
intravenously, intramuscularly or intranasally.
[0121] Examples of suitable pharmaceutical formulations are solid
medicinal forms, such as powders, granules, tablets, in particular
film tablets, lozenges, sachets, cachets, sugar-coated tablets,
capsules, such as hard gelatin capsules and soft gelatin capsules,
suppositories or vaginal medicinal forms, semisolid medicinal
forms, such as ointments, creams, hydrogels, pastes or plasters,
and also liquid medicinal forms, such as solutions, emulsions, in
particular oil-in-water emulsions, suspensions, for example
lotions, injection preparations and infusion preparations, and
eyedrops and eardrops. Implanted release devices can also be used
for administering inhibitors according to the invention. In
addition, it is also possible to use liposomes or microspheres.
When producing the compositions, inhibitors according to the
invention are usually mixed or diluted with an excipient.
Excipients can be solid, semisolid or liquid materials which serve
as vehicles, carriers or medium for the active compound.
[0122] Suitable excipients are listed in the specialist medicinal
monographs. In addition, the formulations can comprise
pharmaceutically acceptable carriers or customary auxiliary
substances, such as glidants; wetting agents; emulsifying and
suspending agents; preservatives; antioxidants; antirritants;
chelating agents; coating auxiliaries; emulsion stabilizers; film
formers; gel formers; odor masking agents; taste corrigents; resin;
hydrocolloids; solvents; solubilizers; neutralizing agents;
diffusion accelerators; pigments; quaternary ammonium compounds;
refatting and overfatting agents; raw materials for ointments,
creams or oils; silicone derivatives; spreading auxiliaries;
stabilizers; sterilants; suppository bases; tablet auxiliaries,
such as binders, fillers, glidants, disintegrants or coatings;
propellants; drying agents; opacifiers; thickeners; waxes;
plasticizers and white mineral oils. A formulation in this regard
is based on specialist knowledge as described, for example, in
Fiedler, H. P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und
angrenzende Gebiete [Encyclopedia of auxiliary substances for
pharmacy, cosmetics and related fields], 4.sup.th edition,
Aulendorf: ECV-Editio-Kantor-Verlag, 1996.
[0123] The following examples serve to explain the invention
without limiting it.
[0124] The magnetic nuclear resonance spectral properties (NMR)
refer to the chemical shifts (.delta.) expressed in parts per
million (ppm). The relative area of the shifts in the .sup.1H NMR
spectrum corresponds to the number of hydrogen atoms for a
particular functional type in the molecule. The nature of the
shift, as regards multiplicity, is indicated as singlet (s), broad
singlet (s. br.), doublet (d), broad doublet (d br.), triplet (t),
broad triplet (t br.), quartet (q), quintet (quint.) and multiplet
(m).
PREPARATION EXAMPLES
Example 1
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide
1.1 1-Allyl-4-(5-nitropyridin-2-yl)piperazine
[0125] 2.0 g (12.61 mmol) of 2-chloro-5-nitropyridine were
dissolved in 8 ml of dimethylformamide, and 3.49 g (25.23 mmol) of
potassium carbonate were added. After that, a solution of 1.75 g
(13.88 mmol) of N-allylpiperazine in 2 ml of dimethylformamide was
added slowly dropwise to the reaction mixture (exothermic
reaction). The reaction mixture was then stirred at room
temperature for 2 hours. After the solvent had been concentrated
down to dryness, the resulting residue was stirred up in 100 ml of
heptane. The precipitate which remained was filtered off with
suction. The filtrate was concentrated, resulting in 720 mg of the
title compound. The precipitate which had been filtered off with
suction was treated with 150 ml of water and extracted three times
with diethyl ether. The organic phase was washed with a saturated
solution of sodium chloride and dried over sodium sulfate. A
further 2.24 g of the title compound were isolated after the
solvent had been filtered and concentrated down to dryness. The
total yield of 1-allyl-4-(5-nitropyridin-2-yl)piperazine was 2.96 g
(95% of theory).
[0126] MS [m+1]: 249.
1.2 6-(4-Allylpiperazin-1-yl)pyridine-3-amine
[0127] 2.2 g (8.86 mmol) of
1-allyl-4-(5-nitropyridin-2-yl)piperazine from Example 1.1 were
dissolved in 150 ml of methanol after which 18 g (79.75 mmol) of
tin(II) chloride dihydrate were added and the mixture was stirred
at 70.degree. C. for 4 hours. After the solvent had been evaporated
down to dryness, water was added to the residue. The aqueous
reaction mixture was made alkaline with dilute sodium hydroxide
solution and then extracted with ethyl acetate. The solid which had
precipitated out was filtered off. After that, the phases were
separated and the aqueous phase was extracted in each case twice
with ethyl acetate and dichloromethane. The combined organic phases
were dried over sodium sulfate. 1.74 g (90% of theory) of the title
compound were obtained after the drying agent had been removed and
the solvent had been evaporated down to dryness.
[0128] MS [m+1]: 219.
1.3N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonami-
de
[0129] 1.4 g (7.97 mmol) of
6-(4-allylpiperazin-1-yl)pyridin-3-ylamine from Example 1.2 and
1.74 g (7.97 mmol) of 4-isopropylbenzenesulfonyl chloride were
dissolved in 30 ml of tetrahydrofuran at room temperature. 3.3 ml
(23.91 mmol) of triethylamine were then added to this mixture.
After that, the reaction mixture was stirred overnight at room
temperature. After the solvent had been evaporated to dryness,
water was added to the residue. The aqueous reaction mixture was
made acid with 1N hydrochloric acid and extracted twice with
diethyl ether. After that, the aqueous phase was made alkaline (pH
9-10) with a 1N aqueous solution of sodium hydroxide and then
extracted twice with diethyl ether. After the combined organic
phases had been dried over sodium sulfate, the drying agent had
been filtered off and the solvent had been evaporated down to
dryness, the resulting residue was chromatographed on silica gel
using cyclohexane/ethyl acetate (45:55% to 100% ethyl acetate). The
filtrate was evaporated down to dryness. The resulting residue was
thoroughly stirred in 10 ml of heptane, filtered off in suction and
dried, with 1.93 g (61% of theory) of the title compound being
obtained.
[0130] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 7.7 (s,
1H); 7.6 (d, 2H); 7.4 (d, 1H); 7.3 (d, 2H); 6.6 (d,1H); 6.4
(bs,1H); 5.9 (m,1H); 5.2 (m, 2H); 3.5 (m, 4H); 3.1 (m, 2H); 3.0 (m,
1H); 2.5 (m, 4H); 1.2 (d, 6H).
[0131] MS [m+1]: 401.
Example 2
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-propylbenzenesulfonamide
[0132] 373 mg of the title compound were obtained in an analogous
manner to that described in Example 1.3 when starting with
4-n-propylbenzenesulfonyl chloride.
[0133] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 7.7 (m,
1H); 7.6 (m, 2H); 7.4 (d, 1H); 7.3 (m, 2H); 6.6 (d, 1H); 6.3 (bs,
1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.5 (m, 4H); 3.1 (m, 2H); 2.6 (m,
2H); 2.5 (m, 4H); 1.7 (m, 2H); 0.9 (m, 3H).
[0134] MS [m+1]: 401.
Example 3
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-butylbenzenesulfonamide
[0135] 405 mg of the title compound were obtained in an analogous
manner to that described in Example 1.3 when starting with
4-n-butylbenzenesulfonyl chloride.
[0136] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 7.7 (m,
1H); 7.6 (m, 2H); 7.4 (d, 1H); 7.3 (m, 2H); 6.6 (d, 1H); 6.2 (bs,
1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.5 (m, 4H); 3.0 (m, 2H);
[0137] 2.7 (m, 2H); 2.5 (m, 4H); 1.6 (m, 2H); 1.4 (m, 2H); 0.9 (m,
3H).
[0138] MS [m+1]: 415.
Example 4
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonam-
ide
[0139] 500 mg of the title compound were obtained in an analogous
manner to that described in Example 1.3 when starting with
4-trifluoromethylbenzenesulfonyl chloride.
[0140] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 7.9 (d,
2H); 7.8 (m, 3H); 7.3 (d, 1H); 6.6 (d, 1H); 5.9 (m, 1H); 5.2 (m,
2H); 3.5 (m, 4H); 3.1 (m, 2H); 2.5 (m, 4H).
[0141] MS [m+1]: 427.
Example 5
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-ethylbenzenesulfonamide
Hydrochloride
[0142] The Example 1.3 was repeated with 4-ethylbenzenesulfonyl
chloride being used instead of 4-isopropylbenzenesulfonyl chloride.
The resulting reaction product was converted into the hydrochloride
with ethereal hydrochloric acid, with 480 mg (please complete) of
the title compound being obtained.
[0143] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.5 (bs,
1H); 10.0 (s, 1H); 7.8 (d, 2H); 7.6 (d, 2H); 7.4 (m, 3H); 6.9 (d,
1H); 6.0 (m, 1H); 5.5 (m, 2H); 4.3 (m, 2H); 3.8 (m, 2H); 3.4 (m,
2H); 3.3 (m, 2H); 3.0 (m, 2H); 2.7 (m, 2H); 1.2 (t, 3H).
[0144] MS [m+1]: 387 (free base).
Example 6
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-vinylbenzenesulfonamide
Hydrochloride
[0145] Example 1.3 was repeated with 4-vinylbenzenesulfonyl
chloride being used instead of 4-isopropylbenzenesulfonyl chloride.
The resulting reaction product was converted into the hydrochloride
with ethereal hydrochloric acid, with 300 mg of the title compound
being obtained.
[0146] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.1
(bs,1H); 10.0 (s,1H); 7.8 (d,1H); 7.6 (m, 4H); 7.3 (d, 1H); 6.9 (d,
1H); 6.8 (dd, 1H); 6.0 (m, 2H); 5.5 (m, 3H); 4.3 (m, 2H); 3.8 (m,
2H); 3.4 (m, 2H); 3.2 (m, 2H); 3.0 (m, 2H).
[0147] MS [m+1]: 385 (free base).
Example 7
4-Isopropyl-N-(6-piperazin-1-ylpyridin-3-yl)benzenesulfonamide
[0148] 95 mg (0.1 mmol) of
tris-(dibenzylideneacetone)dipalladium(0) and 44 mg (0.1 mmol) of
1,4-bis-(diphenylphosphino)butane were dissolved in 10 ml of
tetrahydrofuran under an argon atmosphere. A solution composed of
1.1 g (2.75 mmol) of
N-[6-(4-allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide
from Example 1.3 1 in 3 ml of tetrahydrofuran was then added
dropwise to the reaction mixture. After that, a solution of 386 mg
(2.5 mmol) of 2-mercaptobenzoic acid in 2 ml of tetrahydrofuran was
added dropwise to the reaction mixture and the mixture was stirred
at room temperature for 90 minutes. A solution of a further 386 mg
(2.5 mmol) of 2-mercaptobenzoic acid in 2 ml of tetrahydrofuran was
then added dropwise to the reaction mixture. The reaction mixture
was stirred overnight at room temperature and, after that, the
solvent was evaporated down to dryness. 150 ml of water were added
to the resulting residue, after which the mixture was made acid
with 1N aqueous hydrochloric acid and extracted three times with
diethyl ether. The aqueous phase was then made alkaline, to
pH>11, with a 1N aqueous solution of sodium hydroxide and
subsequently extracted three times with dichloromethane. After
that, the aqueous phase was adjusted to pH 8-9, saturated with an
aqueous solution of sodium chloride and, after that, extracted
several times with dichloromethane. 840 mg (82% of theory) of the
title compound were obtained after the combined organic phases had
been dried over sodium sulfate and the solvent had been filtered
and evaporated down to dryness.
[0149] .sup.1H-NMR (400 MHz, CDCl.sub.3): .delta. [ppm] 7.7 (d, I
H); 7.6 (d, 2H); 7.4 (dd, 1H); 7.3 (d, 2H); 6.6 (d, 1H); 3.5 (m,
4H); 3.0 (m, 5H); 1.2 (d, 6H).
[0150] MS [m+1]: 361.
Example 8
N-{6-[4-(Cyclohexylmethyl)piperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenes-
ulfonamide Hydrochloride
[0151] 150 mg (0.42 mmol) of
4-isopropyl-N-(6-piperazin-1-yl-pyridin-3-yl)-benzenesulfonamide
from Example 7 and 51 mg (0.46 mmol) of cyclohexanealdehyde were
dissolved in 5 ml of dichloromethane and 40 ,l (0.62 mmol) of
glacial acetic acid under a nitrogen atmosphere. 133 mg (0.63 mmol)
of sodium trisacetoxyborohydride were then added. The mixture was
stirred at room temperature for 90 minutes and, after that, the
solvent was evaporated down to dryness. The resulting residue was
taken up in water and this mixture was made to pH>11 with a 1N
aqueous solution of sodium hydroxide. After that, the aqueous
reaction mixture was extracted with diethyl ether. After the
organic phase had been dried over sodium sulfate and the solvent
had been filtered and evaporated down to dryness, the resulting
residue was converted into the hydrochloride with ethereal
hydrochloric acid, resulting in 156 mg (76% of theory) of the title
compound.
[0152] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): .delta. [ppm] 10.4 (bs,
1H); 10.0 (s,1H); 7.8 (d, 1H);
[0153] 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 4.2 (m,
2H); 3.5 (m, 2H); 3.4 (m, 2H); 3.0 (m, 5H); 1.8 (m, 3H); 1.7 (m,
3H); 1.2 (m, 9H); 1.0 (m, 2H).
[0154] MS [m+1]: 457 (free base).
[0155] The compounds of Examples 9 to 12 were prepared in an
analogous manner.
Example 9
N-[6-(4-Isobutylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide
Hydrochloride
[0156] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): .delta. [ppm] 10.4 (bs,
1H); 10.0 (s, 1H); 7.8 (m, 1H); 7.6 (d, 2H); 7.5 (d, 2H); 7.4
(m,1H); 6.9 (d,1H); 4.2 (d, 2H); 3.5 (d, 2H); 3.4 (m, 2H); 3.0 (m,
5H); 2.1 (m, 1H); 1.2 (d, 6H); 1.0 (d, 6H).
[0157] MS [m+1]: 417 (free base).
Example 10
4-Isopropyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]benzenesulfonamide
[0158] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 7.7 (d,
1H); 7.6 (d, 2H); 7.4 (dd, 1H); 7.3 (d, 2H); 6.6 (d, 1H); 3.5 (m,
4H); 3.0 (m, 1H); 2.5 (m, 4H); 2.3 (s, 3H); 1.2 (d, 6H).
[0159] MS [m+1]: 375.
Example 11
N-[6-(4-Ethylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide
Hydrochloride
[0160] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): .delta. [ppm] 10.4 (bs,
1H); 10.0 (s, 1H); 7.8 (d, 1H);
[0161] 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 4.3 (m,
2H); 3.5 (m, 2H); 3.2 (m, 2H); 3.1 (m, 2H); 3.0 (m, 3H); 1.3 (m,
3H); 1.2 (d, 6H).
[0162] MS [m+1]: 389 (free base).
Example 12
N-{6-[4-(Cyclopropylmethyl)piperazin-1-yl]pyridin-3-yl}-4-isopropylbenzene-
sulfonamide Hydrochloride
[0163] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): .delta. [ppm] 10.8 (bs,
1H); 10.0 (s, 1H); 7.8 (d, 1H);
[0164] 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d,1H); 6.9 (d, IH); 4.3 (m,
2H); 3.6 (m, 2H); 3.3 (m, 2H); 3.0 (m, 5H); 1.2 (d, 6H); 1.1
(m,1H); 0.6 (m, 2H); 0.4 (m, 2H).
[0165] MS [m+1]: 415 (free base)
Example 13
N-[6-(4-Allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfo-
namide Hydrochloride
13.1 3-Methyl-1-(5-nitropyridin-2-yl)piperazine
[0166] 872 mg (6.31 mmol) of potassium carbonate were added to a
solution of 500 mg (3.15 mmol) of 2-chloro-5-nitropyridine in 7 ml
of dimethylformamide. After that, a solution of 350 mg (3.32 mmol)
of 2-methylpiperazine in 3 ml of dimethylformamide was slowly added
dropwise to the reaction mixture while cooling with ice (exothermic
reaction). The reaction mixture was stirred for 1 hour while
cooling with ice and then stirred overnight at room temperature.
After the solvent had been evaporated to dryness, the residue was
taken up in water and this mixture was extracted three times with
diethyl ether. The combined organic phases were dried over sodium
sulfate, filtered and evaporated to dryness, with
3-methyl-1-(5-nitropyridin-2-yl)piperazine (Yield: 650 mg, 89% of
theory) being obtained.
[0167] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 9.0 (s,1H);
8.2 (d,1H); 6.6 (d,1H), 4.4 (m, 2H); 3.2 (m,1H); 3.1 (m,1H); 2.9
(m, 2H); 2.7 (m,1H); 1.2 (m, 3H).
[0168] .sup.13C-NMR (125 MHz, CDCl.sub.3): 160.4 (C); 146.5 (CH);
134.9 (C); 133.0 (C); 104.5 (CH); 52.2 (CH.sub.2); 50.6 (CH); 45.7
(CH.sub.2); 45.4 (CH.sub.2); 19.6 (CH.sub.3).
13.2 1-Allyl-2-methyl-4-(5-nitropyridin-2-yl)piperazine
[0169] 630 mg (2.72 mmol) of
3-methyl-1-(5-nitropyridin-2-yl)piperazine from Example 13.1 and
267 III (3.09 mmol) of allyl bromide were dissolved in 10 ml of
dimethylformamide. 1.2 ml (8.4 mmol) of triethylamine were then
added dropwise to the solution. After the mixture had been stirred
at room temperature for 1 hour, a further 65 .mu.l (0.75 mmol) of
allyl bromide were added dropwise to the reaction mixture, which
was then stirred for a further hour. After that, a further 65 .mu.l
(0.75 mmol) of allyl bromide and 0.5 ml (3.6 mmol) of triethylamine
were added dropwise. The mixture was then stirred overnight at room
temperature. After the solvent had been evaporated down to dryness,
the resulting residue was taken up in water and this solution was
made alkaline using a 1N aqueous solution of sodium hydroxide.
After that, the aqueous reaction mixture was extracted three times
with diethyl ether. The combined organic phases were dried over
sodium sulfate, filtered and evaporated down to dryness, with 707
mg (90% of theory) of the title compound being obtained.
[0170] MS [m+1]: 263.
13.3 6-(4-Allyl-3-methylpiperazin-1-yl)pyridine-3-amine
[0171] 4.975 g (22.05 mmol) of tin(II) chloride dihydrate were
added to a solution of 707 mg (2.45 mmol) of
1-allyl-2-methyl-4-(5-nitropyridin-2-yl)piperazine from Example
13.2 in 50 ml of methanol and the resulting mixture was stirred at
70.degree. C. for 90 minutes. After the solvent had been evaporated
down to dryness, water was added to the resulting residue and the
mixture was made alkaline using a dilute aqueous solution of sodium
hydroxide. After that, the aqueous reaction mixture was extracted
with ethyl acetate. The solid which had precipitated out was
filtered off with suction and the phases were separated. The
aqueous phase was extracted with dichloromethane. After that, the
combined organic phases were dried over sodium sulfate, filtered
and evaporated down to dryness. The resulting title compound was
used in the next step without any further purification.
[0172] MS [m+1]: 233.
13.4
N-[6-(4-Allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenze-
nesulfonamide Hydrochloride
[0173] 305 mg (1.31 mmol) of
6-(4-allyl-3-methylpiperazin-1-yl)pyridin-3-ylamine from Example
13.3 and 301 mg (1.38 mmol) of 4-isopropylbenzenesulfonyl chloride
were dissolved in 10 ml of tetrahydrofuran at room temperature,
after which 0.55 ml (3.94 mmol) of triethylamine was added
dropwise. After that, the reaction mixture was stirred overnight at
room temperature. After the solvent had been evaporated down to
dryness, the resulting residue was treated with water and the
mixture was made acid with 1N hydrochloric acid and extracted twice
with diethylether. The aqueous phase was made alkaline, to pH 9-10,
using a 1N aqueous solution of sodium hydroxide and then extracted
twice with diethyl ether. After the combined organic phases had
been dried over sodium sulfate and the solvent had been filtered
and evaporated down to dryness, the resulting residue was purified
by column chromatography (cyclohexane/ethylacetate from 50:50 to
20:80). After that, the filtrate was evaporated down to dryness.
The resulting residue was converted into the hydrochloride using
ethereal hydrochloric acid, with 417 mg (74% of theory) of the
title compound being obtained.
[0174] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .epsilon.[ppm] 11.3
(bs, 1H); 10.0 (s, 1H); 7.8 (d, 1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3
(d, 1H); 6.9 (d,.sub.1H); 6.0 (m, 1H); 5.5 (m, 2H); 4.3 (m, 1H);
4.0 (m, 1H); 3.7 (m, 1H); 3.4 (m, 1H); 3.2 (m, 3H); 3.0 (m, 3H);
1.4 (d, 3H); 1.2 (d, 6H).
[0175] MS [m+1]: 415 (free base).
Example 13a
N-{6-[4-Allyl-(3S)-methylpiperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenesu-
lfonamide (S Enantiomer as Free Base)
[0176] The preparation was effected in analogy with the preparation
of the racemic compound, with enantiomerically pure
(2S)-methylpiperazine being used in step 13.1 instead of racemic
2-methylpiperazine.
[0177] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.3 (bs,
1H); 10.0 (s, 1H); 7.8 (s, 1H);
[0178] 7.6 (d, 2H); 7.4 (d, 1H); 7.3 (d, 1H); 6.9 (d, 1H); 6.0 (m,
1H); 5.5 (m, 2H); 4.3 (m, 2H); 4.0 (m, 1H); 3.7 (m, 1H); 3.4 (m,
1H); 3.2 (m, 2H); 3.1 (m, 1H); 3.0 (m, 2H).1.4 (d, 3H); 1.2 (d,
6H).
[0179] MS [m+1]: 415 (free base)
Example 14
4-Isopropyl-N-[6-(3-methyl-4-propylpiperazin-1-yl)pyridin-3-yl]benzenesulf-
onamide Hydrochloride
[0180] 100 mg (0.24 mmol) of
N-[6-(4-allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulf-
onamide hydrochloride from Example 13.4 were dissolved in 10 ml of
ethyl acetate, after which 10 mg of palladium on active charcoal
(10%) were added and the mixture was stirred overnight at room
temperature under a hydrogen atmosphere. After that, the catalyst
was filtered off and the filtrate was evaporated down to dryness.
After 1 ml of dichloromethane had been added to the resulting
residue, diethyl ether was slowly added dropwise until the solution
became cloudy. The reaction mixture was stirred for 30 minutes and
the precipitate which had formed was filtered off with suction. The
filtrate was evaporated down to dryness, after which the residue
was dissolved in a 1:1 mixture of dichloromethane and diethyl ether
and converted into the hydrochloride by adding ethereal
hydrochloric acid. 71 mg (63% of theory) of the title compound were
obtained.
[0181] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.9 (bs,
1H); 10.0 (s, 1H); 7.8 (d, 1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d,
1H); 6.9 (d,1H); 4.2 (m, 2H); 3.6 (m, 1H); 3.4-3.0 (m, 7H); 1.7 (m,
2H); 1.4 (d, 3H); 1.2 (d, 6H); 0.9 (m, 3H).
[0182] MS [m+1]: 417 (free base).
Example 14a
4-Isopropyl-N-{6-[(3S)-methyl-4-propylpiperazin-1-yl]pyridin-3-yl}benzenes-
ulfonamide as Free Base (S Enantiomer)
[0183] The preparation was effected in analogy with the preparation
of the racemic compound, with enantiomerically pure
(2S)-methylpiperazine being used instead of racemic
2-methylpiperazine.
[0184] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 9.7
(s,1H); 7.7 (s,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.2 (d, 1H); 6.7
(d,1H); 3.8 (m, 2H); 2.9 (m, 2H); 2.8 (m, 1H); 2.6 (m, 2H); 2.3 (m,
1H), 2.1 (m, 2H); 1.4 (m, 2H); 1.2 (d, 6H); 1.0 (m, 3H); 0.8 (m,
3H). MS [m+1]: 417 (free base)
Example 15
N-[5-(4-Allylpiperazin-1-yl)pyridin-2-yl]-4-isopropylbenzenesulfonamide
Hydrochloride
15.1 1-Allyl-4-(6-nitropyridin-3-yl)piperazine
[0185] 315 mg (2.5 mmol) of N-allylpiperazine were dissolved in 5
ml of toluene under an argon atmosphere. 93 mg (0.1 mmol) of
tris-(dibenzylideneacetone)dipalladium(0) (Pd.sub.2dba.sub.3), 126
mg (0.2 mmol) of 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl
(BINAP), 1.14 g (3.5 mmol) of cesium carbonate and 515 mg (2.54
mmol) of 5-bromo-2-nitropyridine were then added and the mixture
was stirred at 120.degree. C., in a microwave oven, for 4 hours.
After the reaction mixture had cooled down to room temperature, a
saturated aqueous solution of ammonium chloride was added. After
that, the aqueous reaction mixture was extracted three times with
in each case 50 ml of ethyl acetate. After the organic phase had
been dried over sodium sulfate, the drying agent had been filtered
off and the solvent had been evaporated down to dryness, the
residue was chromatographed through silica gel using ethyl
acetate/methanol (4:1), with 304 mg (46% of theory) of the title
compound being obtained.
[0186] .sup.1H-NMR (400 MHz, CDCl.sub.3): .delta. [ppm] 8.2 (m,
2H); 7.2 (dd, 1H); 5.9 (m, 1H); 5.3 (m, 2H); 3.5 (m, 4H); 3.1 (m,
2H); 2.6 (m, 4H).
[0187] MS [m+1]: 249
15.2 5-(4-Allylpiperazin-I -yl)pyridine-2-amine
[0188] 300 mg (1.21 mmol) of
1-allyl-4-(6-nitropyridin-3-yl)piperazine from Example 15.1 were
dissolved in 20 ml of methanol, after which 2.18 g (9.67 mmol) of
tin(II) chloride dihydrate were added and the mixture was stirred
at 70.degree. C. for 2 hours. After the solvent had been evaporated
down to dryness, the resulting residue was treated with water and
this mixture was made alkaline using a dilute aqueous solution of
sodium hydroxide and extracted with ethyl acetate. The solid which
had precipitated out was filtered off with suction. The phases were
then separated and the aqueous phase was extracted three times with
ethyl acetate. The combined organic phases were dried over sodium
sulfate, filtered and evaporated down to dryness, with 183 mg (69%
of theory) of the title compound being obtained.
[0189] MS [m+1]: 219.
15.3
N-[5-(4-Allylpiperazin-1-yl)pyridin-2-yl]-4-isopropylbenzenesulfona-
mide hydrochloride
[0190] 520 mg (2.38 mmol) of
5-(4-allylpiperazin-1-yl)pyridin-2-ylamine and 495 mg (2.26 mmol)
of 4-isopropylbenzenesulfonyl chloride were dissolved in 5 ml of
tetrahydrofuran at room temperature, after which 1.0 ml (7.15 mmol)
of triethylamine was added dropwise and the mixture was stirred at
40-50.degree. C. for 6 hours. After the solvent had been evaporated
down to dryness, the resulting residue was treated with water and
this mixture was made acid using 1N aqueous hydrochloric acid and
extracted twice with diethyl ether. The aqueous phase was made
alkaline, to pH 9-10, using a 1N aqueous solution of sodium
hydroxide and then extracted twice with ethyl acetate. After the
combined organic phases had been dried over sodium sulfate, the
drying agent had been filtered off and the solvent had been
evaporated down to dryness, the resulting residue was
chromatographed on silica gel using ethyl acetate. After the
solvent had been removed, the resulting residue was brought into
solution using a little diethyl ether in dichloromethane and then
converted into the hydrochloride using ethereal hydrochloric acid.
415 mg (44% of theory) of the title compound were obtained.
[0191] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.6
(bs,1H); 7.9 (d,1H); 7.8 (d, 2H); 7.5 (dd,1H); 7.4 (d, 2H); 7.1
(d,1H); 6.0 (m,1H); 5.5 (m, 2H); 3.7 (m, 4H); 3.4 (m, 2H); 3.1 (m,
4H); 3.0 (m,1H); 1.2 (d, 6H).
[0192] .sup.13C-NMR (100 MHz, DMSO-d.sub.6): .delta. [ppm] 153.3
(C); 144.5 (C); 141.6 (C); 138.4 (C); 134.3 (CH); 127.3 (CH); 127.0
(CH); 126.8 (CH); 124.8 (CH.sub.2); 113.8 (CH); 57.3 (CH.sub.2);
49.6 (CH.sub.2); 45.2 (CH.sub.2); 33.3 (CH); 23.4 (CH.sub.3).
[0193] MS [m+1]: 401.
Example 16
N-[2-(4Allylpiperazin-1-yl)pyrimidin-5-yl]-4-isopropylbenzenesulfonamide
16.1 2-(4-Allylpiperazin-1-yl)-5-nitropyrimidine
[0194] 114 mg (2.38 mmol) of 50% sodium hydride were added, under a
nitrogen atmosphere and while cooling with ice, to a solution of
273 mg (2.17 mmol) of N-allylpiperazine in 5 ml of
dimethylformamide. After 30 minutes, a solution of 440 mg (2.17
mmol) of 2-(methylsulfone)-5-nitropyrimidine in 5 ml of
dimethylformamide was added dropwise to the reaction mixture. After
10 minutes, 70 ml of water were added and the reaction mixture was
extracted twice with in each case 50 ml of ethyl acetate. After the
combined organic phases had been dried over sodium sulfate, the
drying agent had been filtered off and the solvent had been
evaporated to dryness, 535 mg (99% of theory) of the title compound
were obtained.
[0195] .sup.1H-NMR (400 MHz, CDCl.sub.3): .delta. [ppm] 9.0 (s,
2H); 5.8 (m, 1H); 5.2 (m, 2H); 4.0 (m, 4H); 3.1 (m, 2H); 2.5 (m,
4H).
[0196] MS [m+1]: 250.
16.2 2-(4-Allylpiperazin-1-yl)pyrimidine-5-amine
[0197] 3.84 g (17.0 mmol) of tin(II) chloride dihydrate were added
to a solution of 530 mg (2.13 mmol) of
2-(4-allylpiperazin-1-yl)-5-nitropyrimidine from Example 16.1 in 20
ml of methanol and, after that, the reaction mixture was heated at
reflux for 1 hour. After the solvent had been evaporated to
dryness, the residue was treated with saturated aqueous sodium
chloride solution and then made alkaline using dilute aqueous
sodium hydroxide solution. After that, the aqueous reaction mixture
was extracted with ethyl acetate. The solid which had precipitated
out was filtered off with suction. The phases were then separated
and the aqueous phase was extracted in each case twice with ethyl
acetate and dichloromethane. After the combined organic phases had
been dried over sodium sulfate, the drying agent had been filtered
off and the solvent had been evaporated down to dryness, 220 mg
(46% of theory) of the title compound were obtained.
16.3
N-[2-(4-Allylpiperazin-1-yl)pyrimidin-5-yl]-4-isopropylbenzenesulfo-
namide
[0198] 216 mg (0.98 mmol) of
2-(4-Allylpiperazin-1-yl)pyrimidin-5-ylamine from Example 16.2 and
215 mg (0.98 mmol) of 4-isopropylbenzenesulfonyl chloride were
dissolved in 20 ml of tetrahydrofuran at room temperature, after
which 0.4 ml (3.0 mmol) of triethylamine was added dropwise and the
mixture was stirred at room temperature overnight. After the
solvent had been evaporated down to dryness, water was added to the
resulting residue. The aqueous reaction mixture was made acid using
1N aqueous hydrochloric acid and extracted twice with diethyl
ether. The aqueous phase was made alkaline to pH 9-10, using a 1N
solution of sodium hydroxide and then extracted three times with
diethyl ether. The combined organic phases were dried over sodium
sulfate. The residue which was obtained after filtering off the
drying agent and evaporating the solvent down to dryness was
thoroughly stirred with a mixture composed of heptane and diethyl
ether, filtered off with suction and dried, with 71 mg (18% of
theory) of the title compound being obtained.
[0199] .sup.1H-NMR (500 MHz, CDCl.sub.3): .delta. [ppm] 8.0 (s,
2H); 7.7 (d, 2H); 7.3 (d, 2H); 6.2 (bs, 1H); 5.9 (m, 1H); 5.2 (m,
2H); 3.8 (m, 4H); 3.1 (m, 2H); 3.0 (m, 1H); 2.5 (m, 4H); 1.3 (d,
6H).
[0200] MS [m+1]: 402.
Example 17
4-Isopropyl-N-[2-(4-propylpiperazin-1-yl)pyrimidin-5-yl]benzenesulfonamide
Hydrochloride
[0201] 70 mg (0.17 mmol) of
N-[2-(4-allylpiperazin-1-yl)pyrimidin-5-yl]-4-isopropylbenzenesulfonamide
from Example 16.3 were dissolved in 30 ml of ethyl acetate, after
which 10 mg of palladium on active charcoal (10%) were added and
the mixture was stirred at room temperature for 2 hours under a
hydrogen atmosphere. The catalyst was then filtered off and the
filtrate was concentrated by evaporation. The residue was brought
into solution using 25 ml of diethyl ether and converted into the
hydrochloride with ethereal hydrochloric acid, resulting in 58 mg
(76% of theory) of the title compound being obtained.
[0202] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.0 (bs,
1H); 10.0 (s, 1H); 8.1 (s, 2H); 7.7 (d, 2H); 7.5 (d, 2H); 4.6 (m,
2H); 3.5 (m, 2H); 3.4 (m, 2H); 3.0 (m, 5H); 1.7 (m, 2H); 1.3 (d,
6H); 0.9 m, 3H).
[0203] MS [m+1]: 404 (free base).
EXAMPLE 18
N-[6-(4-Allylpiperazin-1-yl)pyrimidin-4-yl]-4-isopropylbenzenesulfonamide
18.1 N-(6-Chloropyrimidin-4-yl)-4-isopropylbenzenesulfonamide
[0204] 996 mg (5.0 mmol) of isopropylbenzenesulfonamide were
dissolved in 20 ml of dimethyl sulfoxide, after which 288 mg (6.0
mmol) of 50% sodium hydride were added and the mixture was stirred
at room temperature for 30 minutes. 819 mg (5.5 mmol) of
4,6-dichloropyrimidine were then added and the reaction mixture was
stirred overnight at room temperature. Subsequently, the mixture
was heated at 90.degree. C. for 3 hours and, after that, stirred at
120.degree. C., in a microwave oven, for 30 minutes. After the
reaction mixture had cooled down to room temperature, it was
diluted with 150 ml of water, neutralized with citric acid and
extracted three times with diethyl ether. The residue, which was
obtained after drying with sodium sulfate and after removing the
solvent, was dissolved in 100 ml of diethyl ether and extracted
with an aqueous solution of sodium hydrogen carbonate. The aqueous
phase was acidified and extracted with diethyl ether. The organic
phase was dried, filtered and evaporated down to dryness, with 440
mg (28% of theory) of the title compound being obtained.
[0205] MS [m+1]: 312.
18.2
N-[6-(4-Allylpiperazin-1-yl)pyrimidin-4-yl]-4-isopropylbenzenesulfo-
namide
[0206] 430 mg (1.38 mmol) of
N-(6-chloropyrimidin-4-yl)-4-isopropylbenzenesulfonamide from
Example 18.1 were dissolved in 3 ml of dimethyl sulfoxide, after
which 1.74 g (13.79 mmol) of N-allylpiperazine were added and the
mixture was stirred overnight. Subsequently, the reaction mixture
was stirred at 100.degree. C., in a microwave oven, for 45 minutes.
After the reaction mixture had cooled down to room temperature, it
was diluted with 50 ml of water. After that, the aqueous reaction
mixture was extracted with 50 ml of ethyl acetate and the
precipitate was filtered off with suction, with 190 mg (34% of
theory) of the title compound being obtained.
[0207] .sup.1H-NMR (400 MHz, CDCl.sub.3): .delta. [ppm] 8.4 (s,
1H); 7.8 (d, 2H); 7.3 (d, 2H); 6.1 (s, 1H); 5.9 (m, 1H); 5.2 (m,
2H); 3.6 (m, 4H); 3.0 (m, 3H); 2.5 (m, 4H); 1.3 (d, 6H).
[0208] MS [m+1]: 402.
Example 19
N-[2-(4-Allylpiperazin-1-yl)pyridin-5-yl]-4-bromobenzenesulfonamide
hydrochloride
[0209] The preparation was effected in analogy with Example 1.3,
with 4-bromobenzenesulfonyl chloride being used instead of
4-isopropylbenzenesulfonyl chloride. The reaction product which was
obtained was converted into the hydrochloride using ethereal
hydrochloric acid, resulting in 398 mg of the title compound.
[0210] MS [m+1]: 436/438
Example 20
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-cyclopropylbenzenesulfonamide
[0211] 398 mg (0.84 mmol) of
N-[6-(4-allylpiperazin-1-yl)pyridin-3-yl]-4-bromobenzenesulfonamide
from Example 19, 101 mg (1.18 mmol) of cylcopropylboronic acid, 676
mg (3.19 mmol) of K.sub.3PO.sub.4 and 26 mg (0.09 mmol) of
tricyclohexylphosphine were dissolved in 4 ml of toluene and 0.2 ml
of water under a nitrogen atmosphere. 10 mg (0.04 mmol) of
palladium(II) acetate were then added and the mixture was stirred
at 100.degree. C., in a microwave oven, for one hour. After the
solvent had been evaporated down to dryness, the resulting residue
was treated with water and the mixture was then extracted with
ethyl acetate. Because the phases only separated poorly, the finely
divided solid was filtered off. The aqueous phase was extracted
twice with ethyl acetate. After the combined organic phases had
been dried over sodium sulfate and the solvent had been filtered
and evaporated down to dryness, the resulting residue was purified
by column chromatography.
[0212] MS [m+1]: 399
[0213] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.1 (bs,
1H); 9.9 (s, 1H); 7.8 (s, 1H); 7.6 (d, 2H); 7.3 (dd, 1H); 7.2 (d,
2H); 6.9 (d, 1H); 6.0 (m, 1H); 5.5 (d, 2H); 4.3 (m, 2H); 3.8 (m,
2H); 3.4 (m, 2H); 3.2 (m, 2H); 3.0 (m, 2H); 2.0 (m,1H); 1.0 (m,
2H); 0.8 (m, 2H).
[0214] The compounds of the following examples 21 to 40 were
prepared in analogous manner:
Example 21
4-Isopropyl-N-[2-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamide
Hydrochloride
[0215] MS [m+1]: 403 (free base).
Example 22
4-Isopropyl-N-[2-(3,5-dimethyl-4-propylpiperazin-1-yl)pyridin-3-yl]-benzen-
esulfonamide trifluoroacetate
[0216] MS [m+1]: 431 (free base).
Example 23
N-[2-(4-Allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzen-
esulfonamide Hydrochloride
[0217] MS [m+1]: 441 (free base).
Example 24
N[6-(4-Allyl-3,5-dimethylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesu-
lfonamide Hydrochloride
[0218] MS [m+1]: 429 (free base)
Example 25
N-[6-(4-Allyl-3,5-dimethylpiperazin-I
-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonamide
Hydrochloride
[0219] MS [m+1]: 455 (free base)
Example 26
N[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonami-
de
[0220] MS [m+1]: 427
Example 27
4-Bromo-N-[6-(4-propylpiperazin-1yl)pyridin-3-yl]-benzenesulfonamide
[0221] MS [m+1]: 439/441
Example 28
4-Chloro-N-[6-(4-propylpiperazin-1yl)pyridin-3-yl]-benzenesulfonamide
[0222] MS [m+1]: 395
Example 29
4-Isopropyl-N-[6-(5-propyl-2,5-diazabicyclo[2.2.1]hept-2-yl)pyridin-3-yl]--
benzenesulfonamide Hydrochloride
[0223] MS [m+1]: 415 (free base)
Example 30
N-[6-(5-Allyl-2,5-diazabicyclo[2.2.1]hept-2-yl)pyridin-3-yl]-4-isopropylbe-
nzenesulfonamide Hydrochloride
[0224] MS [m+1]: 413 (free base)
Example 31
N-[6-(4-Propylpiperazin-1-yl)pyridin-3-yl]-4-vinylbenzenesulfonamide
Hydrochloride
[0225] MS [m+1]: 387 (free base)
Example 32
N-{6-[4-(3-Fluoropropyl)piperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenesul-
fonamide Hydrochloride
[0226] MS [m+1]: 421 (free base)
Example 33
4-Isopropyl-N-[6-(4-prop-2-yn-1-ylpiperazin-1-yl)pyridin-3-yl]-benzenesulf-
onamide Hydrochloride
[0227] MS [m+1]: 399 (free base)
Example 34
4-Ethyl-N-[6-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamide
Hydrochloride
[0228] MS [m+1]: 389 (free base)
Example 35
N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-chlorobenzenesulfonamide
Hydrochloride
[0229] MS [m+1]: 393 (free base)
Example 36
4-Isopropyl-N-(4-methyl-6-piperazin-1-ylpyridin-3-yl)-benzenesulfonamide
Hydrochloride
[0230] MS [m+1]: 375 (free base)
Example 37
N-[6-(4-Allylpiperazin-1-yl)-4-methylpyridin-3-yl]-4-isopropylbenzenesulfo-
namide Hydrochloride
[0231] MS [m+1]: 415 (free base)
Example 38
4-Isopropyl-N-[4-methyl-6-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesul-
fonamide Hydrochloride
[0232] MS [m+1]: 417 (free base)
Example 39
N-[4-Methyl-6-(4-propylpiperazin-1-yl)pyridin-3-yl]-4-vinylbenzenesulfonam-
ide Hydrochloride
[0233] MS [m+1]: 401 (free base)
Example 40
N-[6-(4-Butylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide
Hydrochloride
[0234] MS [m+1]: 417 (free base)
Example 41
N-{6-[(3S)-4-Ethyl-3-methylpiperazin-1-yl]pyridin-3-yl}-4-isopropylbenzene-
sulfonamide Hydrochloride
[0235] MS [m+1]: 403 (free base)
Example 42
N-[2-(4-Allylpiperazin-1-yl)pyridin-5-yl]-4-(N-pyrrolidinyl)benzenesulfona-
mide Fumarate
[0236] Reaction of 0.300 g of
6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine (1.29 mmol) and
0.282 g of 4-isopropylbenzene-1-sulfonyl chloride (1.29 mmol) in 10
ml of a mixture of pyridine and dichloromethane (1:2) yielded 0.465
g (87%) of the title compound as a white solid. The title compound
was onverted into the fumarate salt in methanol by addition of
fumaric acid.
[0237] MS [m+1]: 415
[0238] .sup.1H-NMR (400 MHz, CH.sub.3OD): .delta. [ppm]: 7.6 (d,
2H), 7.5 (d, 2H), 7.3 (m, 1H), 7.2 (m, 1H), 7.1 (d, 1H), 6.5 (d,
1H), 5.9 (m, 1H), 5.4 (m, 2H), 3.5 (m, 5H), 3.0 (m, 4H), 2.8 (m,
2H), 1.9 (s, 3H), 1.2 (m, 6H).
Example 43
4-Isopropyl-[N-[2-(4-allylpiperazin-1-yl)-6-methylpyridin-5-yl]-4-(N-pyrro-
lidinyl)benzenesulfonamide, Fumarate
[0239] Reaction of 0.300 g of
6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine (1.29 mmol) and
0.282 g of 4-isopropylbenzene-1-sulfonyl chloride (1.29 mmol) in 10
ml of a mixture of pyridine/dichloromethane (1:2) yielded 0.465 g
(87%) of the title compound as a white solid. The title compound
was onverted into the fumarate salt in methanol by addition of
fumaric acid.
[0240] MS [m+1]: 415
[0241] .sup.1H-NMR (400 MHz, MeOD): .delta. (ppm] 7.6 (d, 2H), 7.5
(d, 2H), 7.3 (m, 1H), 7.2 (m, 1H), 7.1 (d, 1H), 6.5 (d, 1H), 5.9
(m, 1H), 5.4 (m, 2H), 3.5 (m, 5H), 3.0 (m, 4H), 2.8 (m, 2H), 1.9
(s, 3H), 1.2 (m, 6H).
Example 44
4-tert-Butyl-[N-[2-(4-allylpiperazin-1-yl)-6-methylpyridin-5-yl]-benzenesu-
lfonamide, Fumarate
[0242] Reaction of 0.300 g of
6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine (1.29 mmol) and
0.300 g of 4-tert-butylbenzene-1-sulfonyl chloride (1.29 mmol) in
10 ml of a mixture of pyridine/dichloromethane (1:2) yielded 0.525
g (95%) of the title compound as a white solid. The title compound
was onverted into the fumarate salt in methanol by addition of
fumaric acid.
[0243] MS [m+1]: 429
[0244] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 9.3 (s,
2H), 8.6 (d, 2H), 7.8 (m,1H), 7.4 (m, 2H), 7.0 (d,1H), 6.6 (d, 1H),
5.8 (m,1H), 5.2 (m, 2H), 3.4 (m, 4H), 2.9 (m, 2H), 2.4 (m, 4H), 1.9
(s, 3H), 1.3 (s, 9H).
Example 45
4-tert-pentyl-[N-[2-(4-Allylpiperazin-1-yl)-6-methylpyridin-5-yl]-benzenes-
ulfonamide, Fumarate
[0245] Reaction of 0.300 g of
6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine (1.29 mmol) and
0.318 9 of 4-tert-pentylbenzene-1-sulfonyl chloride (1.29 mmol) in
10 mL pyridinedichloromethane (1:2) yielded 0.564 g (99%) of the
title compound as a white solid. The title compound was onverted
into the fumarate salt in methanol by addition of fumaric acid.
[0246] MS [m+1]: 443
[0247] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 9.3 (s,
2H), 8.6 (d, 2H), 7.8 (m, 1H), 7.4 (m, 2H), 7.0 (d,1H), 6.5 (d,1H),
5.8 (m,.sub.1 IH), 5.2 (m, 2H), 3.4 (m, 4H), 3.0 (m, 2H), 2.4 (m,
4H), 1.9 (s, 3H), 1.6 (m, 2H), 1.2 (s, 6H), 0.6 (t, 3H).
[0248] The compounds of Examples 46 to were prepared in analogous
manner:
Example 46
4-Ethyl-N-[6-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-benzenes-
ulfonamide, Hydrochloride
[0249] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .epsilon.[ppm] 10.9
(bs, 1H); 10.0 (s, 1H); 7.8 (m, 1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3
(dd, 1H); 6.9 (d, 1H); 4.3 (m, 2H); 3.5-2.9 (m, 7H); 2.7 (m, 2H);
1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 4H); 0.9 (t, 3H).
[0250] MS [m+1]: 403
Example 47
N-[6-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-4-vinylbenzenesu-
lfonamide, Hydrochloride
[0251] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.4 (bs,
1H); 10.0 (s, 1H); 7.8 (s, 1H); 7.7(m, 4H); 7.3 (d, 1H); 6.9 (d,
1H); 6.8 (dd, 1H); 6.0 (d, 1H); 5.4 (d, 1H); 4.3 (m, 2H); 3.5 (m,
1H); 3.3-2.9 (m, 6H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 1H); 0.9
(t, 3H).
[0252] MS [m+1]: 401
Example 48
N-[6-((S)-4-Allyl-3-methyl-piperazin-1-yl)-2-methoxy-pyridin-3-yl]-4-isopr-
opyl-benzenesulfonamide, Hydrochloride
[0253] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.1 (bs,
1H); 9.2 (s, 1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (m, 1H); 6.4 (m,
1H); 6.0 (m, 1H); 5.5 (m, 2H); 4.3 (m, 2H); 4.0 (m, 1H); 3.7 (m,
2H); 3.4-3.2 (m, 5H); 3.1 (m, 1H); 3.0 (m, 2H); 1.4 (m, 2H); 1.2
(m, 7H).
[0254] MS [m+1]: 445
Example 49
4-Isopropyl-N-[2-methoxy-6-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyridin--
3-yl]-benzenesulfonamide, Hydrochloride
[0255] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.8 (bs,
1H); 9.3 (s, 1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (m, 1H); 6.4 (m,
1H); 4.2 (m, 2H); 3.5-3.2 (m, 8H); 3.1 (m, 1H); 3.0 (m, 2H); 1.7
(m, 2H); 1.4 (m, 2H); 1.2 (m, 7H); 0.9 (t, 3H).
[0256] MS [m+1]: 447
Example 50
N-[6-((S)-4-Allyl-3-ethyl-piperazin-1-yl)-pyridin-3-yl]-4-isopropylbenzene-
sulfonamide, Hydrochloride
[0257] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.2
(bs,1H); 10.0 (s, 1H); 7.8 (d, 1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3
(m, 1H); 6.9 (d, 1H); 6.0 (m, 1H); 5.5 (m 2H); 4.2 (m, 2H); 4.0 (m,
2H); 3.4-3.0 (m, 6H); 1.7 (m, 2H); 1.2 (d, 6H); 1.0 (t, 3H).
[0258] MS [m+1]: 429
Example 51
N-[6-((S)-3-Ethyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-4isopropylbenzene-
sulfonamide, Hydrochloride
[0259] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.2
(bs,1H); 10.2 (s,1H); 7.8 (d,1H); 7.7 (d, 2H); 7.4 (m, 3H); 7.0 (d,
1H); 4.2 (m, 2H); 3.6-3.0 (m, 8H); 2.0 (m, 1H); 1.7 (m, 3H); 1.2
(d, 6H); 1.0 (m, 6H).
[0260] MS [m+1]: 431
Example 52
4-Isopropyl-N-(2-piperazin-1-yl-pyrimidin-5-yl)-benzenesulfonamide
[0261] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 8.0 (s,
2H); 7.6 (d, 2H); 7.4 (d, 2H); 3.6 (m, 4H); 3.0 (m, 1H); 2.7 (m,
4H); 1.2 (d, 6H).
[0262] MS [m+1]: 362
Example 53
N-[2-(4-Ethyl-piperazin-1-yl)-pyrimidin-5-yl]-4-isopropyl-benzenesulfonami-
de, Hydrochloride
[0263] .sup.1H-NMR (400 MHz, D.sub.2O): .delta. [ppm] 7.7 (s, 2H);
7.3 (d, 2H); 7.1 (d, 2H); 4.3 (m, 2H); 3.3 (m, 2H); 3.0 (m, 4H);
2.7 (m, 3H); 1.0 (t, 3H); 0.9 (d, 6H).
[0264] MS [m+1]: 390
Example 54
N-[2-((S)-4-Ethyl-3-methyl-piperazin-1-yl)-pyrimidin-5-yl]-4-isopropylbenz-
enesulfonamide, Hydrochloride
[0265] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.7
(bs,1H); 10.0 (s,1H); 8.1 (m, 2H); 7.6 (d, 2H); 7.4 (d, 2H); 4.6
(m, 2H); 3.4 (m, 4H); 3.2 (m, 1H); 3.0 (m, 3H); 1.4 (m, 2H); 1.2
(m, 10H).
[0266] MS [m+1]: 404
Example 55
N-[2-((S)-4-Allyl-3-methyl-piperazin-1-yl)-pyrimidin-5-yl]-4-isopropylbenz-
enesulfonamide, Hydrochloride
[0267] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.0 (bs,
1H); 10.0 (s, 1H); 8.1 (s, 2H); 7.6 (d, 2H); 7.4 (d, 2H); 6.0 (m,
1H); 5.5 (m, 2H); 4.6 (m, 2H); 4.0 (m, 2H); 3.7 (m, 2H); 3.3 (m,
3H); 3.0 (m,1H); 1.4 (m, 2H); 1.2 (m, 7H).
[0268] MS [m+1]: 416
Example 56
4-Isopropyl-N-[2-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyrimidin-5-yl]ben-
zenesulfonamide, Hydrochloride
[0269] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.6
(bs,1H); 10.0 (s,1H); 8.1 (m, 2H); 7.6 (d, 2H); 7.4 (d, 2H); 4.5
(m, 2H); 3.5 (m, 2H); 3.3 (m, 3H); 3.0 (m, 3H); 1.7 (m, 2H); 1.4
(m, 2H); 1.2 (m, 7H); 0.9 (t, 3H).
[0270] MS [m+1]: 418
Example 57
4-Ethyl-N-[2-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyrimidin-5-yl]benzene-
sulfonamide, Hydrochloride
[0271] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.8
(bs,1H); 10.0 (s,1H); 8.1 (m, 2H); 7.6 (d, 2H); 7.4 (d, 2H); 4.5
(m, 2H); 3.5 (m, 2H); 3.3 (m, 3H); 3.0 (m, 2H); 2.7 (m, 2H); 1.7
(m, 2H); 1.4 (m, 2H); 1.2 (m, 4H); 0.9 (t, 3H).
[0272] MS [m+1]: 404
Example 58
N-[2-((S)-3-Methyl-4-propyl-piperazin-1-yl)-pyrimidin-5-yl]-4-Vinylbenzene-
sulfonamide, Hydrochloride
[0273] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 10.7 (bs,
1H); 10.0 (s, 1H); 8.1 (d, 2H); 7.7 (m, 4H); 6.8 (dd, 1H); 6.0 (d,
1H); 5.5 (d, 1H); 4.5 (m, 2H); 3.5 (m, 2H); 3.3 (m, 3H); 3.0 (m,
2H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 1H); 0.9 (t, 3H).
[0274] MS [m+1]: 402
Example 59
4-Isopropyl-benzenesulfonic acid
6-(4-allyl-piperazin-1-yl)-pyridin-3-yl Ester
[0275] 59.1 4-Isopropyl-benzenesulfonic acid 6-chloro-pyridin-3-yl
ester
[0276] A reaction flask containing 500 mg of 6-chloropyridin-3-ol
(3.86 mmol) and 844 mg of 4-isopropyl-benzenesulfonylchloride (0.20
mmol) in dry tetrahydrofurane (10 ml) was flushed with N2. 1.6 ml
of triethylamine were added and the reaction mixture was stirred at
room temperature for 2 h. Thereby 4-isopropyl-benzenesulfonic acid
6-chloropyridin-3-yl ester ester was obtained in 98% yield.
[0277] MS [m+1]: 312
[0278] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 8.1 (d,
1H); 7.8 (d, 2H); 7.6 (m, 4H); 3.0 (m, 1H); 1.2 (d, 6H).
[0279] 59.2 4-Isopropyl-benzenesulfonic acid
6-(4-allyl-piperazin-1-yl)-pyridin-3-yl ester
[0280] A flask containing 45 mg of palladium(II) acetate (0.2
mmol), 126 mg of BINAP (0.20 mmol) and 0.233 mg of sodium
tert-butylate in dry toluene (15 mL) was flushed with nitrogen
1.275 g of 1-allylpiperazin (10 mmol) were added and the reaction
mixture was heated to 50.degree. C. 630 mg of
4-isopropyl-benzenesulfonic acid 6chloro-pyridin-3-yl ester (2.0
mmol) were dissolved in toluene and the solution was slowly added
over a period of 10 minutes into the reaction mixture with
stirring. The mixture was heated to reflux with stirring for 7 h.
Thereby 4-isopropyl-benzenesulfonic acid
8(4-allyl-piperazin-1-yl)-pyridin-3-yl ester was obtained in 21%
yield.
[0281] MS [m+1]: 402
[0282] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 7.8 (d,
2H); 7.7 (d, 1H); 7.6 (d, 2H); 7.2 (dd, 1H); 6.8 (d, 1H); 5.8 (m,
1H); 5.2 (m, 2H); 3.5 (m, 4H); 3.0 (m, 3H); 2.5 (m, 4H); 1.2 (d,
6H).
Example 60
4-Isopropyl-benzenesulfonic acid
6-(4-propyl-piperazin-1-yl)-pyridin-3-yl Ester, Hydrochloride
[0283] In a reaction flask 5 mg of palladium on charcoal were added
to 50 mg of 4-isopropylbenzenesulfonic acid
6-(4-allyl-piperazin-1-yl)-pyridin-3-yl ester from example 59(0.12
mmol) in dry ethyl acetate (5 ml). The atmosphere was then charged
with hydrogen gas and the reaction mixture was stirred at room
temperature for 1 hour. Thereby, 4-isopropyl-benzenesulfonic acid
6-(4-propyl-piperazin-1-yl)-pyridin-3-yl ester were obtained in 58%
yield. The compound was converted into its hydrochloride salt by
addition of HCl in ether.
[0284] MS [m+1]: 404
[0285] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. [ppm] 11.0
(bs,1H); 7.8 (m, 3H); 7.6 (d, 2H); 7.3 (dd,1H); 6.9 (d,1H); 4.3 (d,
2H); 3.5 (d, 2H); 3.3 (dd, 2H); 3.0 (m, 5H); 1.7 (m, 2H); 1.3 (d,
6H); 0.9 (t, 3H).
[0286] Examples of galenic administration forms
A) Tablets
[0287] Tablets of the following composition are pressed on a tablet
press in the customary manner:
[0288] 40 mg of substance from Example 2
[0289] 120 mg of corn starch
[0290] 13.5 mg of gelatin
[0291] 45 mg of lactose
[0292] 2.25 mg of Aerosil.RTM. (chemically pure silicic acid in
submicroscopically fine dispersion)
[0293] 6.75 mg of potato starch (as a 6% paste)
B) Sugar-coated tablets
[0294] 20 mg of substance from Example 2
[0295] 60 mg of core composition
[0296] 70 mg of saccharification composition
[0297] The core composition consists of 9 parts of corn starch, 3
parts of lactose and 1 part of 60:40 vinylpyrrolidone/vinyl acetate
copolymer. The saccharification composition consists of 5 parts of
cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate
and 1 part of talc. The sugar-coated tablets which had been
prepared in this way are subsequently provided with a gastric
juice-resistant coating.
Biological investigations--receptor binding studies:
[0298] The substance to be tested was either dissolved in
methanol/Chremophor) (BASF-AG) or in dimethyl sulfoxide and then
diluted with water to the desired concentration.
[0299] Dopamine D.sub.3 receptor:
[0300] The assay mixture (0.250 ml) was composed of membranes
derived from .about.10.sup.6 HEK-293 cells possessing stably
expressed human dopamine D.sub.3 receptors, 0.1 nM
[.sup.125I]-iodosulpride and incubation buffer (total binding) or,
in addition, test substance (inhibition curve) or 1 .mu.M spiperone
(nonspecific binding). Each assay mixture was run in triplicate.
The incubation buffer contained 50 mM tris, 120 mM NaCl, 5 mM KCl,
2 mM CaCl.sub.2, 2 mM MgCl.sub.2 and 0.1% bovine serum albumin, 10
.mu.M quinolone and 0.1% ascorbic acid (prepared fresh daily). The
buffer was adjusted to pH 7.4 with HCl.
[0301] Dopamine D.sub.2L receptor:
[0302] The assay mixture (1 ml) was composed of membranes from
.about.10.sup.6HEK-293 cells possessing stably expressed human
dopamine D.sub.2L receptors (long isoform) and 0.01 nM [.sup.125I]
iodospiperone and incubation buffer (total binding) or, in
addition, test substance (inhibition curve) or 1 .mu.M haloperidol
(nonspecific binding). Each assay mixture was turn in
triplicate.
[0303] The incubation buffer contained 50 mM tris, 120 mM NaCl, 5
mM KCl, 2 mM CaCl.sub.2, 2 mM MgCl.sub.2 and 0.1% bovine serum
albumin. The buffer was adjusted to pH 7.4 with HCl.
[0304] Measurement and analysis:
[0305] After having been incubated at 25.degree. C. for 60 minutes,
the assay mixtures were filtered through a Whatman GF/B glass fiber
filter under vacuum using a cell collecting device. The filters
were transferred to scintillation viols using a filter transfer
system. After 4 ml of Ultima Gold.RTM. (Packard) have been added,
the samples were shaken for one hour and the radioactivity was then
counted in a Beta-Counter (Packard, Tricarb 2000 or 2200CA). The
cpm values were converted into dpm using a standard quench series
and the program belonging to the instrument.
[0306] The inhibition curves were analyzed by means of iterative
nonlinear regression analysis using the Statistical Analysis System
(SAS) which is similar to the "LIGAND" program described by Munson
and Rodbard.
[0307] In these tests, the compounds according to the invention
exhibit very good affinities for the D.sub.3 receptor (<100 nM,
frequently <50 nM) and bind selectively to the D.sub.3 receptor.
The results of the binding tests are given in Table 1.
TABLE-US-00002 TABLE 1 Example K.sub.i (D.sub.3) [nM] Selectivity
vs. D.sub.2L* 1 3.0 232 2 5.5 25 3 5.9 15 5 11.4 108 6 9.7 169 7
11.4 68 10 7.5 93 11 6.2 77 13 3.6 131 13a 2.7 96 14 2.5 81 14a 1.5
184 16 3.8 131 17 8.2 148 19 36.9 91 22 21.9 22 24 25.0 47 27 21.4
55 28 25.3 67 29 16.9 31 30 11.1 17 31 14.0 96 32 17.0 74 34 9.6 73
35 26.6 51 36 5.4 50 37 2.7 86 38 17.2 22 39 34.6 30 42 5.3 33 43
1.1 80 44 1.4 41 45 1.4 24 46 7.1 50 47 6.1 118 48 0.8 21 49 0.4 19
50 9.9 57 51 3.1 101 52 14.2 63 53 8.8 149 54 2.3 84 55 2.9 159 56
1.6 399 57 7.3 234 58 6.2 254 59 16.2 75 60 17.4 47
*K.sub.i(D.sub.3)/K.sub.i(D.sub.2L)
* * * * *